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The purpose of this study was to examine hope both as a powerful discursive 
element in health-related literature and as a discursive practice in cancer research 
decision-making by patients, family caregivers, and physician researchers in a quaternary 
cancer research center. The practice of hope is an important activity for people diagnosed 
with cancer, but the unexamined, taken-for-granted practice of hope may exert undue 
influences on the decision-making/informed consent process for cancer research 
participation.  
A genealogy (systematic analysis that illustrates the complex and often 
contradictory historical influences that culminate in the construction of a concept) of 
hope was created using philosophical, theological, and literary resources. From these 
analyses, major discourse practices of hope were identified. Then a focused discourse 
analysis of representative articles on hope published between 1999 and 2008 in the 
journal Advances in Nursing Science examined how influential articles reify hope as an 
object—with the result that hope becomes something that can be given or taken away 
from patients, thus limiting the scope of how hope can be enacted.  
A secondary analysis of 109 transcripts from 25 cancer patients enrolled in Phase 
II clinical trials for hematopoietic stem cell transplants analyzed how patients, family 
caregivers (n=20), and physician researchers (n=10) used metaphors to construct and 





indentify patterns of persuasion present in the transcripts that reinforced the hope 
imperative for patients to enroll in cancer research. Metaphors used by study participants 
were not neutral, but rather were dynamic forces that demonstrated the discursive power 
and hope’s centrality to decision-making for cancer research participation.  
Current discursive practices of the informed consent process allow researchers to meet 
federal and regulatory guidelines while ignoring a potential coerciveness in the 
underlying dynamics of hope-for-cure and the hope imperative. The implications of this 
work are significant for bioethics. This work will help cancer research professionals 
engage in informed consent processes that minimize the elements of coercion. The 
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Statement of the Problem  
 “This is my only hope.” These words are spoken often by cancer patients trying to 
decide on their medical care and research options. For some, the decision to participate in a 
clinical trial comes after multiple courses of conventional chemotherapy or radiation have 
been unsuccessful in treating the disease. In such circumstances, the research associated 
with a clinical trial seems to offer the opportunity for hope. Hope is also invoked by 
investigators who believe that clinical trials may improve cancer care and outcomes for 
patients. Participation requires that patients give their consent to clinical trials under strict 
regulatory guidelines as set forth in the Code of Federal Registration (CFR) 45 § 16:124. 
These guidelines are established by the U. S. Department of Health and Human Services 
(DSHS) to protect human study subjects; the guidelines specifically mandate that decision 
to participate be autonomous, free of coercion, and adequately informed. 
 Quaternary cancer research centers most often offer interventions in Phase I/II 
clinical trials. The available information used to seek patient consent is preliminary at 
best and may be a component of a larger research program within the institution. 
Researchers are vested in finding new interventions that will decrease cancer morbidity 




quaternary cancer research centers are there because care at the tertiary level has proven 
unsuccessful in the treatment of their cancer. They are now seeking the newest—and 
possibly the only—alternative for potential disease amelioration. Because people facing 
these life-threatening conditions are especially vulnerable to coercion, researchers must 
take extra efforts to assure that the informed consent process is free from coercion and is 
promising in terms of potential cure via research. 
  The guidelines governing informed consent are legal mandates. Those mandates 
dictate that informed consent must be a process that is autonomous, that is free of coercion, 
and that provides adequate information regarding relevant facts, risks, and potential 
benefits and alternatives (DSHS, 2010). In addition to legal mandates, there is also a moral 
obligation on the part of healthcare providers to facilitate decision-making for cancer 
patients in a way that educates and allows for independent decision-making.  While 
important, legal mandates fall short in acknowledging the role hope plays in decision-
making. Hope is actually practiced by both patients and researchers in a mostly taken-for-
granted and unexamined manner. As legal mandates are used to protect human study 
subjects, those involved also need to acknowledge the powerful cultural and historical 
implications of hope in decision-making.   
 
Purpose 
 This qualitative, exploratory study utilized a discursive examination of hope as 
articulated by patients, family members, and investigators as decisions were made to 
participate in cancer research. The broad, long-range goal of this study was to provide 
additional information about hope in decision-making for clinical research participation 




free of coercion. This close textual examination was meant to facilitate a full exploration 
and to provide clarity for researchers and patients regarding this most important yet 
taken-for-granted factor of hope in cancer decision-making. 
  Studies of hope in health care have been done primarily from an objectivist 
perspective—one that framed hope as a “thing” existing independent of social interactions. 
In the post-positivist theoretical model, hope was quantifiable and measurable; 
measurements were then used to inform providers how to assist patients in the pursuit of 
hope. If hope was assumed to be a single universal construct, that assumption clearly 
limited the analysis of the ways hope was operationalized in a larger population. 
   Hope as a practice should be acknowledged for the power it exerts in human 
relationships and particularly in decision-making processes.  Hope is generally assumed 
to have only a positive effect in the lives of individuals, yet hope can be practiced in a 
coercive or exploitative manner, especially in a vulnerable population such as cancer 
patients. This study is intended to provide insight into how hope is practiced in a 
quaternary cancer research center by patients, family members, and researchers. 
Information gleaned from this study should generate new knowledge and provide a new 
perspective that will result in improved support of decision-making processes.  
 
Research Questions 
  Previous research has evaluated hope as an objective entity and has even proposed 
ways to measure and quantify it. This study examined hope as it is used by cancer 
patients, family members, and researchers in the decision to participate in research at a 




Informed consent is not only a legal, mandated process, it is an ethical imperative.  
Researchers need to fully comprehend the unexamined assumptions of hope as it is 
invoked by patients, family members, and themselves throughout the informed consent 
process. This study examined how hope influences the decision-making process for 
cancer research participation. 
Hope can be used as a noun or a verb; in cancer care, it is often referred to as a 
verb or an action—something people do. Hope as action is a practice or activity in which 
people engage in the trajectory of a cancer diagnosis. In this study, hope was analyzed as 
a “practice” or an enactment coconstructed by patients, family members, and researchers. 
The choice of the term practice was purposeful, as it allowed the analysis of hope as an 
action and removed it from the usual category of a “thing” that can be possessed. 
 
Specific Aims 
Aim #1:  To explore the historical discourses of hope.  
RQ 1A. What are the discourses of hope that influence how people construct the 
practice of hope? 
Aim #2:  To examine how people with cancer practice hope in making 
decisions about their participation in cancer research.  
RQ 2A.  How, when, and why do patients, family members, and researchers 
employ the construct of hope?  
RQ 2B.   What words do patients, family members, and researchers use as 
metaphors for hope? 




Aim  #3: To describe cultural, religious, political, and traditional words that 
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BACKGROUND AND SIGNIFICANCE 
 
Cancer Research 
 More than 1,550 people die every day of cancer; the estimated death rate in 
America from cancer in 2007 was 559,650, rendering cancer the second most common 
cause of death after heart disease (American Cancer Society, 2007). Despite cancer 
ranking as the second most common cause of death, the National Cancer Institute (NCI) 
Cancer Trends Progress Report of 2007 stated that the United States death rate dropped 
for the first time since 1993. When adjusted for delayed reporting, the incidence of new 
cancers was found to be relatively stable since the mid-1990s.  Clinical research is 
integral to improving the morbidity and mortality associated with cancer.  
 
Hope and Cancer 
 Hope has been described as a construct that provides comfort, encouragement, 
and an ability to look toward a more positive future. Several studies have identified hope 
as a resource for coping with cancer, providing the patient with strategies for managing 
the disease and engaging valuable social support (DuFault & Benita, 1985; Ebright & 
Lyons 2002; Ersek, 1992; Rustoen & Wiklund 2000). In the present study, a theoretical 
model of hope was derived from the premise that hope is integral to how people clarify, 




  Hope has been identified as a key component in cancer patients’ coping, 
resilience, empowered self-care, and perceived quality of life (Dickerson et al., 2006; 
DuFault & Benita, 1985; Eliott & Olver, 2002; Ersek, 1992; Saleh & Brockopp, 2001). 
Several studies have drawn direct links between patients’ faith experiences and 
connection to God as correlative with the experience of hope (Dickerson et al., 2006; 
Eliott & Olver, 2002; Ersek, 1992; Herth, 1989, 1992, 2000; Rustoen & Wiklund, 2000;  
Saleh & Brockopp, 2001;).   
The association of hope with religion and spirituality is a strong cultural theme in 
America; the relationship between hope and religion can be useful in determining how 
hope is practiced by people.  This relationship between hope and religion can also be a 
hindrance in understanding the notion of hope as practiced outside the Western traditions 
of Judeo-Christian religions. 
 
Hope as an Interpersonal Interaction 
   Communication is foundational for patients who are navigating the decision-
making process following a diagnosis of cancer.  Several studies have reported that 
communication between the patient and the provider significantly impacted how much 
influence hope had for the patient (Caocci et al., 2006; Eliott & Olver, 2002; Thorne, 
Hislop, Kuo, & Armstrong, 2006). Recognizing how much influence providers can 
exercise on patients established the need to investigate the nature and power of that 
influence on the practice of hope. 
  Dissemination of statistical information has been correlated with the increase of 
hope in cancer patients. The use of survival statistics in conferences between patients and 




facts in numeric format and resented the implications contained in the numeric risk 
statements. Yet despite this resentment, some patients reported taking comfort in the 
statistics. This held true even when fewer than 5% of patients with that particular cancer 
survived. The tiniest chance of survival carried with it hope for the individual to be 
among those who would comprise the survival statistic (Thorne et al., 2006). 
  Communication in all its forms had recognized significance for patients engaged 
in decision-making and in the cocreation of hope. Consent conferences included verbal 
conversations accompanied by written documents.  Beyond the one-on-one 
communication between the patient and the investigator, broader communication was an 
influence in the decision-making process.  At one large cancer research center in the 
American southwest, researchers who surveyed patients about a recent media campaign 
for a new chemotherapeutic agent found that the media had an observable effect on 
patients’ awareness of self-care options and provided opportunities to foster hope (Pentz 
et al., 2000). The Internet is another source of social support and information. The 
literature affirmed that decisions to participate in cancer research were influenced by 
patient hope and that hope was created in the context of shared communication in many 
forms (Dickerson et al., 1999). 
 
Measuring Hope 
    Significant work in the investigation of hope and cancer patients has been done by 
Kaye Herth. Herth’s postpositivist theory asserted that hope can be defined and 
measured.  Her initial work in 1989 introduced the Herth Hope Scale (HHS) in a study 
whose purpose was to examine the relationship between a level of hope and a level of 




United States. Herth found that individuals with strong religious faith had a higher level 
of hope and coping response than those without faith or those who reported “weak faith.” 
Herth identified three factors of hope: 1) temporality and future; 2) positive readiness and 
expectancy; and 3) interconnectedness.  
The HHS tool was abbreviated and became the Herth Hope Index (HHI), a name 
by which it is still called. Herth’s work established the “four attributes of hope”—
experiential, spiritual/transcendence, relational, and rational thought.  Most significantly, 
Herth asserted that hope is an important component in the lives of people with cancer 
(Herth, 1989, 1992, 2000).  
The HHI is still considered an exemplar when working with cancer patients and 
the construct of hope. It does have limitations, however, because it is built upon a 
premise of religious and cultural connotations of hope that are noninclusive and are not 
experienced by all people across various cultures. 
 
Hope and Hopelessness 
  In Greek mythology, hope was one of the consignees of Pandora’s Box. Hope—
elpis in Greek—was the last of the contents of the box (or the jar, depending on the 
version of the myth).  Pandora received the box from Zeus or Hermes with a warning to 
never open it. Curiosity got the best of her, however, and when she opened the box, 
Pandora unleashed evil and misfortunes on the entire world population. According to at 
least one version of the myth, Pandora closed the box and left the spirit Hope trapped 
inside. Another version of the myth allowed an intervening time of trials and tribulations 
for the world until Pandora returned to re-open the box; at that time, hope fluttered out 




hope was symbolic of better times promised in the midst of hardships. Another 
interpretation was that elpis/hope was the worst of all evils, since it was a deception. In 
this view, Pandora saved the world by closing the lid and preventing the escape of hope. 
Two divergent conceptualizations of hope emerged from Greek mythology, depending on 
the version of the myth conveyed. The myth of Pandora’s Box set the stage for the 
constructs of hope and hopelessness having interstitial and binary meanings. One does 
not exist without the intrinsic presence of the other.  
 Work in health care has mirrored this dualistic nature of hope. Viewing hope as 
an object that can be quantified and measured, researchers like Herth (2000) have 
designed tools that measure the individual’s level of hope or, conversely, hopelessness. 
Beck created a tool in 1974 to assess hopelessness in psychiatric patients. Observing 
patients struggling with despair, Beck determined they stood in need of reframing their 
feelings of hopelessness in order to replace pessimism with optimism. In essence, they 
needed to replace helplessness with skills of adaptation and coping. To work with these 
very vulnerable people, it was important to predict and to prevent self-harm and suicide, 
so Beck formulated a tool that used 11 items drawn from a repository of pessimistic 
statements made by the physicians who had judged the patients to be hopeless. These 
were combined with nine items from a resource test of attitudes about the future 
structured in a semantic differential format (Beck, Weissman, Lester, & Trexler, 1974).  
Both tools measured the meaning of practicing hope in the presence of an enduring sense 
of hopelessness.  
  Snyder (1995) posited hope as a goal and directed thinking comprised in two 




derived sense of successful agency (goal directed determination) and pathways (planning 
to meet goals)” (p. 357). This theory has been applied to achieving academic success in 
college, to assessing aging in adults, to analyzing young people victimized in early 
adolescence by violence, and finally to assisting people coping with chronic illness 
(Basile et al., 2006; Kylma & Vehvilainen-Julkene, 1997; Snyder et al., 1991; Snyder et 
al., 2002; Valle, Huebner, & Suldo, 2006).  
  Various tools have been designed to measure hope in various populations. Snyder 
created a scale (Hope Scale—HS) to measure hope in a wide variety of people, not just 
cancer patients.  Herth’s Hope Index (HHI) was created to evaluate hope in cancer 
patients. Beck’s Hopelessness Scale (BHS) was created to evaluate hope in psychiatric 
patients. Scales like the HS, HHI, and BHS tap certain dimensions of hope/hopelessness 
but at times only obfuscate understanding of what is constitutive in either the practice of 
hope or of hopelessness.  
 
Decision-Making 
  Federal regulations offer a strict code for how consent for research participation 
should be offered and confirmed (CFR 45 § 16:124) (DSHS, 2010). The federally 
mandated elements required for decision-making include a statement of the research 
purpose; the identification of potential risks and benefits; an explanation of procedures, 
possible compensation, and limits to confidentiality; and a declaration of voluntariness. 
The decision must be based primarily on adequate information. It must be free of 
coercion and be made autonomously (or voluntarily) by the research participant. The 
concept of autonomy is based on the objectivist’s perspective that people are able to be 




move beyond autonomy and substitute agency in its place. The concept of agency is 
further developed in a later section.  
   Nevertheless, there is still a gap in current literature and research on hope when 
addressing the concerns of provider influence on subsequent decision-making about 
enrollment in clinical trials. To begin to address this gap, analyses need to be undertaken 
to demonstrate how people with cancer construct hope and hopelessness. 
   Among cancer patients, the concept of hope is activated almost synchronously 
with the diagnosis. Hope for a cure—or at least for the chance of additional time—is a 
concept commonly employed not only by patients and their loved ones, but also by 
researchers. Extended survival is desired by researchers and those whose livelihood 
depends on continued research programs for possible improvement of morbidity and 
mortality associated with cancer care.  Hope may represent a coercive influence in the 
decision-making process for people with cancer when it leads them to decide for the 
option of research, because that option represents the “only hope” for possible survival.  
When research is offered to patients, the very language used to facilitate informed 
consent sometimes uses words like treatment, therapeutic benefit, hope, and cure. This 
kind of communication may lead patients to perceive research as an intervention with 
certain outcomes—when in reality, research is designed to establish safety and possibly 
efficacy questions, but it has uncertain outcomes.   
   A construct integral to decision-making in clinical research trials is the notion of 
therapeutic misconception —a term that does not distinguish between medical treatment 




consent if patients confuse the difference between research and treatment (Appelbaum, 
Lidz, & Grisso, 2004).   
Informed consent is required by law to be a free and uncoerced process. Without 
such laws, patients may be coerced into considering research studies that hold little 
promise of ameliorating the disease.  
 
Early Phases of Clinical Trials 
   Clinical trials are classified as Phase I, II, III, or IV, according to the research 
question under investigation (NCI, 2008). Phase I trials, the earliest trials, are comprised 
of the first research done in human subjects. They are performed on small populations 
ranging from 10 to 80 participants. The focus of Phase I trials is to identify a safe dose 
and any potential side effects.  
Phase II trials are intended to further identify safety concerns in dosage and to 
ascertain a range of side effects. Populations for Phase II trials are larger, between 100 
and 300 participants. 
Phase III trials are done on larger populations of between 1,000 and 3,000 
participants. They are undertaken to confirm effectiveness of the research intervention in 
comparison to established interventions, to monitor side effects, and to evaluate safety 
parameters in larger groups of people.  
Phase IV studies are postmarketing studies done after a drug has been approved 
and is available on the market.  These studies may be done by companies or investigators 
interested in examining additional information that has not yet been captured by the 




    In the area of oncology research, the Federal Drug Administration (FDA) added a 
policy allowing for earlier access to promising new research interventions through 
various mechanisms, referred to as “expanded access.”  This means that “when no 
satisfactory alternative treatment exists, subjects are generally willing to accept greater 
risks from test articles that may treat life-threatening and debilitating illnesses” (NCI, 
2008; FDA, 2008). While helping bring potentially beneficial drugs to market more 
quickly, this policy has had the unintended consequence that interventions are primarily 
approved in early Phase I–II trials. In other words, many people may face a research 
participation decision before much data have been accumulated. Cancer care at the 
quaternary level is most often entirely research-driven, so referred patients are choosing 
between early-phase clinical trials for disease intervention.  
    As one example, Victoria Wolfe is a woman who participated in several Phase I 
and Phase II clinical trials for her acute promyelocytic leukemia. An ethnographic 
presentation of Wolfe’s journey through decision-making was presented juxtaposed to a 
theoretical framework of the ethical decision-making process by Shannon–Dorcy 
(Shannon Dorcy & Wolfe, 2003). Nurses are often called on to help translate the 
information given to patients for decision-making relative to cancer research 
participation. Shannon Dorcy’s manuscript highlighted the need to acknowledge nurses’ 
role in the research consent process, and underscored the need for nurses to honor the 
fidelity of the relationship while practicing informed consent for research (Shannon 






 Currently there are many subtle and not-so-subtle ways in which hope is 
cocreated by and for people with cancer in the clinical care setting. Hope is a powerful 
activity in which researchers and patients engage while making decisions for cancer 
research participation. People employ hope as a result of their experiences, and hope 
continues to be inculcated throughout their lives. Hope is reinforced and employed in the 
discourses of providers, patients, and family members. The same language of hope is 
often used by researchers and care providers who explain the various treatment and 
research options open to people with cancer. The construct of hope even plays a 
significant role in scientific literature, verifying that the concept of hope is widely 
associated with cancer in scientific discourse. Literature searches of “Cancer & Hope” 
within ProQuest returned 45,084 articles, Pub Med returned 4,158 articles, and Web of 
Science returned 1,683 articles.  
  Given that providers and patients rely on the construct of hope in the clinical 
management of the illness and in options for treatment and research participation, greater 
knowledge is needed on how hope is practiced and perhaps at times exploited. Insight is 
needed into how human beings interpret and construct hope in specific linguistic, social, 
and historical contexts. Research is needed to understand when and how hope is included 
as an influence or an element of coercion in the informed consent process. These findings 
will enhance the process of informed consent and possibly eliminate unintended but 
nonetheless real elements of coercion, since avoiding coercion is both a federally 
mandated regulation and an ethical imperative. Additionally, the research will provide 




dimensions of the cocreation and dynamics of hope. Assumptions that hope is something 
that professional staff can engender in others may be erroneous. In fact, patients may be 
the primary creators of hope and investigators may be inspired to continue their research 
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THEORETICAL AND METHODOLOGICAL FRAMEWORK 
 
Introduction 
  The research questions for this study explored historical discourses of hope; 
examined how people with cancer practice hope in decision-making for cancer research; 
and, finally, described the cultural, religious, political, and other assumptions that frame 
hope relative to decision-making.  A constructivist epistemology was chosen. 
Constructionism provides the foundation for recognizing that truth or meaning exists in 
and because of our interactions with the realities of our world. Meaning is not waiting to 
be found, it is constructed (Crotty, 2003).  
 Constructionism provided a starting point that helped inform and shape how the 
study was designed. The methodology of discourse analysis stemming from the 
constructionist approach as discourse analysis was the study of language in use. Words 
were the textual focus of analysis in the transcripts and were analyzed relative to hope 
and informed consent. The work of Pierre Bourdieu helped in understanding hope as 
constructed in the texts under analysis. Bourdieu’s concept of habitus and additional 
concepts of language—such as ontology, agency, and genealogy—were developed; each 







  Pierre Bourdieu (1930–2002) was a French sociologist who created a theory of 
action around the concept of habitus, a theory that asserted people are the embodiment of 
their class and political positions within society. Bourdieu did not see the historical 
inculcation of an individual’s class to be deterministic. Habitus has a strong component 
of personal agency that assures people have the capacity to make generative choices that 
express individual free will. Bourdieu identified this process of tastes or preference as 
constructs shaped by the home as it is referent to a larger community context or class. 
Class is a collective process organized historically with specific cultural and political 
influence. Habitus served as an expanded model for understanding personal autonomy 
and provided a historical and cultural context for how hope influenced the decision to 
participate in cancer research (Bourdieu, 1997, 1984, 1990).  
 
Habitus 
  The word habitus is Latin for a pattern, characteristic, or condition of the body. 
For Bourdieu, the tapestry of human existence was a blend of personal agency greatly 
influenced by the culturally accessible experiences and choices available to individuals in 
the course of their lives. Bourdieu used habitus to reference socially acquired, embodied 
systems of dispositions or predispositions; he believed that personal choices or 
preferences are neither random nor linear components of an individual’s life.  Habitus is 
not only about moral socialization; it is about personal inclinations, tendencies, and 
propensities in opinions, habits, decorum, and practices in different historical and cultural 
settings. Bourdieu carefully avoided determinism or essentialism as philosophical 




to stimuli.  He believed that change is not a possibility if one’s responses are programmed 
by essentialist determinism and if there is no free will.  
  The ability to make choices while reflexively remaining engaged with the 
researchers and with the societal norms for what constitutes being a “good patient” 
constitutes habitus; it served as the theoretical foundation upon which the study of hope 
in decision-making for cancer patients was built. Hope is part of a social construction of 
reality, and this process is a cooperative one—it never happens in a vacuum. People are 
raised in a social milieu where they learn to comprehend by way of discourse and where 
they assume social practices such as “fitting in” or gaining political power. People 
diagnosed with cancer engage in a reflexive dialogue with cancer researchers and use 
language to produce meaning about what it means to be a patient or to be a researcher. 
 
Language as Ontology 
 Bourdieu (1997) maintained that language was understanding and that language is 
a practice of the construction of meaning in which people reflexively share: 
The constitutive power which is granted to ordinary language lies not in the language 
itself, but in the group which authorizes it and invests it with authority. Official language, 
particularly the system of concepts by means of which the members of a given group 
provide themselves with a representation of their social relations (e.g. the lineage model 
or the vocabulary of honor), sanctions and imposes what it states, tacitly laying down the 
dividing line between the thinkable and the unthinkable, thereby contributing towards the 
maintenance of the symbolic order from which it draws its authority. (p. 21) 
  Bourdieu saw language as a mechanism of power within the sphere of one’s 




recognition of their power and prejudices. Such awareness helps researchers understand 
how much power they have in relationship to the participants in the research. In the case 
of clinical research decision-making, researchers have a responsibility to assure freedom 
from coercion and to provide support for patients making decisions. For Bourdieu, the 
critique of the dominant symbolic order was an exhortation against oppression and 
invoked a responsibility for social justice and accountability on the part of all individuals. 
His philosophical framework is useful because it shares features with early theological 
and religious discourses on hope that advocate an objective reality and free will relative 
to decision-making. 
   A patient’s expectation of what constitutes hope informs the process for choosing 
options for cancer interventions. The combination of influences by which people practice 
hope is knit together in the history of their experiences (the ordinary) and then is manifest 




 Agency is a term that signifies the capacity of individuals to discern, evaluate, and 
form independent motives for action or to implement practices.  Overriding structure 
versus agency is the classic dilemma of free will versus determinism. Do individuals 
exercise agency (free will), or are choices and actions based on social inculcation?   
 Hope and optimism are expectations of society in general when dealing with 
illness and are practiced by patients as well as by researchers. There is a reflexive 
relationship between patients, family members, and researchers as the discourse around 





    This study will provide an overview of the notion of hope and show how a 
genealogy of hope influences the construction and general practice of hope today. To 
draw conclusions about how hope is enacted within the clinical context of cancer 
research decision-making, it is first necessary to explore the complex, often complicated, 
and even contradictory dialectic of hope. This contradictory dialectic is why the model of 
genealogy was chosen for this analysis. Michel Foucault’s concept of “genealogy” was 
built on the work of Nietzsche to examine the relationship of power to the development 
of morals (Foucault, 1972; Nietzsche, 1996).  
 Foucault used genealogy as a valuable asset in the analysis of notions held as 
“truths” in both written and oral discourse. These notions include things like sexuality, 
hope, and other principles often seen as absolutes or as essences with an assumed single 
“truth” or representation. Foucault maintained that most “truth” comes to us in daily life 
not in a linear manner but via an irregular, often contradictory, dynamic process of power 
and influence.  
   Foucault studied discourse rather than language and asserted that discourse is a 
linguistic concept that creates meaning. Discourse, then, is the process of constructing the 
topic as it defines and produces our objects of knowledge.  This is opposed to an 
objectivist epistemology, which says that the object is the source of definition and of 
knowledge itself. Foucault acknowledged discourse as a process, so discourse consists of 
more than the words of a single document, a single text, or an individual source. 
Discourse is a culturally enacted process that includes a broad range of sources that create 




actions do not exist; he merely pointed out that without discourse, there is no meaning 
(Foucault, 1972).   
 
Brief Genealogy of Hope 
   One important discourse regarding hope—elpis—resides in Greek mythology.  
Hope was introduced as either a solace to the world or an instrument of torture, since it is 
ultimately inaccessible.  Another contributing influence in the genealogy of hope is the 
work of Aristotle, who framed hope in a neutral manner.  He also advocated the use of 
inductive reasoning to affirm knowledge in an empirical fashion. If it is objectified, hope 
becomes capable of being seen and measured as a phenomenon (Tredenick & Barnes, 
1976). 
  Another set of historical milestones in this brief genealogy of hope are the 
writings in the New Testament and the Old Testament. Discourses of hope in the Bible 
generally drew on the promise of salvation from the forces of evil, sorrow, hunger, and 
eternal death: “This hope we have is an anchor of the soul, both sure and steadfast, and 
which enters the Presence behind the veil” (Hebrews 6:18).  In 1 Corinthians 13:13, Paul 
wrote that “The greatest spiritual gifts are faith, love and hope.” “Now may the God of 
hope fill you with all joy and peace in believing, that you may abound in hope by the 
power of the Holy Spirit” (Romans 15:12, 13)(New American Bible, 1999).  
 The Aristotlean notion of hope as a virtue was further developed by Thomas Aquinas in 
the thirteenth-century Summa Theologica. He sought to elucidate the role of the virtues 
within a Christian anthropology and explained them as qualities that enable participation 
in divine tranquility while progressing through one’s status as homo viator. According to 




toward a future good of what one might expect to attain (building on the rationalist view 
of hope originally put forth by Aristotle), and the other providing assistance through 
which one attains what one expects or hopes to attain. Aquinas theorized that hope 
resides in the will and that its principal object is eternal happiness, which can only be 
attained with the assistance of God (Aquinas, 1920).  Ultimately, hope attains God by 
leaning on God. Insofar as love may have united us with others, we may hope for others 
as well as for ourselves. 
 We can trace the historical creation of hope by using language. Discourses about 
hope allow for an examination of how hope has been transformed into a set of 
assumptions and reified. Tracing the historical and cultural discourses of hope helps in 
the analysis of the words spoken by cancer patients and their families.  
 
Research Design and Methods 
 This study is an exploratory discursive analysis of existing transcribed interviews. 
A secondary analysis was done on 109 interviews utilizing HyperResearch® software for 
transcript coding. Participants were drawn from within a quaternary cancer research 
center and consisted of patients (n=25), family members (n=20), and researchers (n=10). 
  Demographic data were gathered to examine how this group of primarily White, 
upper-middle-class, Protestant Americans made decisions about participating in cancer 
research. Other demographic criteria needed for understanding the sample context were 
diagnoses, length of time since original diagnosis to current seeking of care at the 
quaternary center, age, gender, self-identified religious or spiritual affiliations, and 
racial/ethnic identifications. These components of demographic data were helpful in 





  Certain themes were identified from the genealogical analysis that were 
instrumental in the second part of the study, the content analysis of the 109 interviews. 
Content analysis is a general term for a variety of types of textual analysis; it involves 
comparing, contrasting, and categorizing data. The investigator performed content 
analysis in the following steps: 1) Creation of a set of codes; 2) Systematic application of 
those codes to the set of textual data; 3) Creation of a matrix of variables from the coded 
textual data; 4) Analysis of the matrix by interpretive methods (Schwandt, 2001).   
  A directed approach to content analysis was used because the categories for 
coding of the transcripts were pre-established. Those pre-established codes became the 
key categories for coding patient, family caregiver, and physician statements (Hsieh & 
Shannon, 2002).  
 
Critical Discourse Analysis 
   Language is a major component of discourse because it serves to construct or 
create the context of whatever the signifier is engaged in signifying. Critical discourse 
analysis allows an examination of the distribution of power as it relates to the practice of 
hope. Discourse enables people to engage in the process of informed consent when 
making decisions about participating in research. Within the social setting of a quaternary 
cancer center, the key actors are patients, family caregivers, and individual researchers. 
Each has a specific role in the social milieu of the consent conference and each is 





   Critical analysis can only be done when there is an adequate comprehension of 
social power and dominance.  There are certain discourses of hope that are privileged by 
prevalence and dominance in social discourse.  In the early Christian church, for 
example, priests had preferential access to written texts and scriptures, so discourse was 
shaped by a religious and theological set of actors whose agency and cultural context 
allowed them to use the concept of hope in a context of poverty and suffering. In addition 
to a larger global overview of dominant discourse, it is necessary to scrutinize the micro 
or unofficial uses of power conveyed in tone, word choice, hesitations, pronoun use, and 
rhetorical style (Fairclough, 2003).  
    Discourse analysis of hope was done on textual data, with intertextuality as a key 
concept. Fairclough (2003) summarized intertextuality in this way: “for any text there is a 
set of other texts and a set of voices which are potentially relevant and potentially 
incorporated into the text” (p. 47).  Fairclough referred not only to the cited or attributed 
voices of others but also to the pervasive voice or even to the hegemonic presence of 
other texts that are knit into a re-contextualization in each text.   
Shared meanings can and do create assumptions within texts. Fairclough (2003) 
identified three major assumptions: existential assumptions, propositional assumptions, 
and value assumptions. Explicit articulation of value is generally easy to assess.  Implicit 
valuation, however, is more difficult to assess and must be culled out of the text for 
successful discourse analysis. The transcribed texts were reviewed for implicit as well as 
explicit assumptions. One prevailing implicit assumption held by participants was the 






Methods and Measures 
Sample for Secondary Analysis 
 Data were collected and secondary analysis was performed on an existing data set 
of 109 transcribed interviews with cancer research patients (n=25), family members 
(n=20), and investigators (n=10). The interviews were conducted over 2 years, 
encompassing a period that spanned from 3 months before participating in the research to 
1 year after participating.  Physicians were interviewed only once; those interviews 
occurred at an independent time point.    
 
Interviews 
  Participants ranged in age from 22 to 72, with 30 males and 25 females 
participating. Four patients died before the day-80 interview (n=21), 5 patients died 
before the day-365 interview, 1 patient withdrew before the final interview, 1 patient did 
not return to the center for his 1-year follow-up appointment, and 2 patients were too ill 
to be interviewed. Five patients did not have identified family caregivers, resulting in the 
n=20. Six caregivers were unable to be interviewed because they had returned to their 
homes prior to the patients’ final interview 1 year following hematopoietic cell transplant 
(HCT). Questions for interviews are listed in Appendix A. Ten attending physicians were 
interviewed at a single time point. See demographic Table 1 at the end of this chapter. 







   The initial interviews identified what influenced patients’ and family members’ 
decisions to participate in early-phase clinical trials.  The interviews also identified when 
the decisions were made to participate in early-phase clinical trials. Additionally, 10 
physicians were interviewed for their perspective on the decision-making process for 
patients and family members. The current study is a secondary analysis of that primary 
data set.  
Hope was not the focus of the primary study, but the notion of hope arose enough 
to warrant the secondary analysis.  Future work will benefit from the opportunity to ask 
purposeful questions specifically related to hope. Even though specific questions about 
hope were not asked in this study, the spontaneous comments about hope justified further 
study of hope and its role in decision-making in cancer research.   
The current study is also limited because the original sample had very little 
cultural and ethnic diversity.  The data relative to hope and research came from a fairly 
singular perspective of White, upper-middle-class Americans.  
 
Protection of Human Subjects 
  The study was reviewed by the University of Utah Institutional Review Board 
(IRB) as well as by the Fred Hutchinson Cancer Research Center (FHCRC) Institutional 
Review Board to assure regulatory compliance with research practices and the protection 
of human subjects involved in research. A full review was conducted by the FHCRC 
IRB, and an expedited review was done by the University of Utah.  A waiver of consent 





Risks to the Subjects 
 A convenience sample of 25 patients, 20 family caregivers, and 10 physicians 
comprised the parent sample. To be eligible for the study, potential participants had to be 
English-speaking, 18 years of age or older, and legally able to make their own decisions 
regarding care. (Children were not included in the study, because the primary assessment 
was of adult decision-making rather than surrogate decision-making.) Patients who were 
intubated or unable to respond orally to questions were not eligible for the study. Patients 
deemed too ill for study participation by the attending outpatient physician were not 
eligible for the original study because the extra interviews would have represented 
unnecessary stress and burden. All other adult patients who arrived for allogeneic 
transplant for a Phase II protocol at the Seattle Cancer Care Alliance (SCCA) were 
eligible.  
Patients’ health status varied, depending on the status of their disease as they 
entered the FHCRC/SCCA. Generally, the Karnofsky score (a measure of health status) 
of the patients was 80% at the time they entered the study and at the day-80 interview. At 
1 year, patients generally had a 90–100% Karnofsky score.  
 
Sources of Data 
 Research data were collected from participant document reviews and from 
interviews conducted with subjects. In addition, demographic information—such as age, 
gender, race/ethnicity, diagnosis, stage of disease, and course of previous treatments—
was collected. This information was garnered from the patients’ existing medical records 




   Potential risks of the proposed study were minimal. Participants may have 
experienced some emotional discomfort as they described their experiences in the 
original interviews. Patients may also have been fatigued by the interviews. Patients were 
encouraged to defer the interview or request to withdraw from the study if the burden 
seemed too great. One patient did withdraw at day 360 and 1 withdrew the day after 
signing the consent form. The study used existing typed transcripts to avoid causing 
further fatigue or emotional distress to participants. 
  Recruitment for study participation began with contact in the outpatient setting 
(the SCCA) among patients coming to FHCRC/SCCA for allogeneic HCT for a Phase II 
study. The appropriate clinical team pulled the consent form for the study and one of the 
study investigators met with the patient and caregiver to obtain consent for participation 
in the study. The study was explained to potential participants; they were told that refusal 
to participate in the informed consent study did not preclude participation in other clinical 
trials. Patients who agreed to participate in this study were registered through the bio-
statistics clinical office at the FHCRC. They signed a consent form that was kept on file 
in both their medical records and the researchers’ records. All participants received a 
copy of the signed consent for their records.  
 Interviewers were trained in methods for assessing and dealing with discomfort, 
charged emotions, and undue fatigue. Research data were kept confidential in locked file 
cabinets in offices with access available only to the research team. Computers on which 
data were stored had restricted access codes. All study data were stripped of identifiers 






    In a qualitative exploration, it is important that the data source be large enough to 
provide depth and richness to the constructs under examination. The current study used a 
large enough sample (interviews n=109) to compare and contrast discursive enactments 
of hope. The use of a secondary data set enabled the researcher to undertake a robust 
critical analysis of hope as a taken-for-granted concept in the informed consent process. 
The data set represented an opportunity to examine hope as practiced in the discussions 
of decision-making of patients enrolling in Phase II cancer research trials.   
   One goal of the study was to demonstrate that hope does not have to be limited to 
a post-positivist epistemology where it is evaluated in a decontextualized, empirical 
manner; rather, hope can be seen in a constructionist epistemology that acknowledges the 
cultural, historical, and political habitus of hope.  The implications of this work are 
significant for bioethics and ultimately for the informed consent process. Additionally, 
new insight is provided into the applied philosophical and metaphysical discourses of 
hope and how hope is enacted in the care of cancer patients. 
 
Summary 
 The purpose of this study was to examine the concept of hope as it is practiced in 
the quaternary cancer research setting. The literature generally supports the value of hope 
for those who are diagnosed with cancer. Much has been written that acknowledges the 
role of hope and its influence on human beings, especially when those people are coping 
with a cancer diagnosis. The majority of the literature on hope originates from a 
rationalistic empirical framework that reifies hope instead of inviting a comprehensive 




  Cancer research is integral to discovering new methods of disease amelioration.  
Patients who are offered research are often those for whom there are few remaining 
options. To participate in research, patients and their families and researchers engage in a 
procedure called “informed consent.” Implementation of informed consent is mandated 
by the federal government and must include autonomous decision-making, adequate 
information offered by the researcher in a noncoercive manner, awareness of options, and 
voluntariness. These regulatory mandates are established to prohibit the exploitation of 
people participating in research. Intrinsic to the regulatory mandates is the ethical 
imperative not to exploit other human beings and to protect vulnerable participants.   
   Coercion or undue influence in consent is subtle and difficult to define. Guidance 
offered by the United States Department of Health and Human Services states that for 
informed consent to be adequate for those seeking enrollment in research, “known 
benefits should be stated accurately but not exaggerated, and potential or uncertain 
benefits should be stated as such, with clear language indicating how much is known 
about the uncertainty or likelihood of these potential benefits” (NIH, 2008, p. 284).  
Investigators must inform people clearly and avoid enhancing the likelihood of benefit by 
employing the concept of a hope-for-cure. Representing clinical research as the “only 
hope” frames the research option as life-saving and potentially beneficial. Thus, careful 
examination of what people report as significant in influencing their choices for research 
participation is important to help gain an understanding of if and how hope is articulated 
and implemented in the informed consent process. 
  Given the methodology of discourse analysis, the author acknowledges a position 




research and cancer patients. This acknowledgment of her point of entry into formal 
inquiry manifests what Bourdieu classified as habitus. Her sense of distinction 
(perspective) is mediated through habitus (Bourdieu, 1987, p. 170). So it is artificial to 
claim a tabula rasa, or a blank slate, as she formulated her research questions and 
designed the study.  
 
Overview of Specific Analyses 
   The three parts of this study are meant to triangulate the understanding of hope in 
the context of decision-making for cancer research participation. The first part of the 
study began at the most general level—the philosophical level—to identify how hope has 
been primarily objectified and reified in health care literature. A critique of the objectivist 
model of hope was completed as it was represented in published literature.  Articles 
written about hope from the last 10 years (n=3) were critiqued and compared and 
contrasted within a constructivist framework.  The articles were chosen from Advances in 
Nursing Science (1999–2010). Intertextuality, as described by Fairclough (2003), 
facilitated the analysis of inherent assumptions in the three articles. The implication of a 
singular approach to hope is that only certain things can be classified as hope, so the full 
understanding of the breadth of hope and its role in decision-making in cancer patients 
cannot be fully explored or understood.  
 The next two parts of the study utilized discourse analysis of a secondary data set 
of interviews. All 109 interviews used the following codes: Genealogy, Hope as Noun, 
Hope as Verb, Hope as Practiced, Active Voice, Passive Voice, and Metaphors. After the 
codes were applied, a parallel was drawn between discourse and rhetoric—the ancient art 




federal policies, also served as an encounter of patients and family members with the 
researcher. The elements of logos (logic of the argument), pathos (emotions of the 
audience), and ethos (trustworthiness or credibility of the researcher) were then used as 
further refinements in coding of the category “Hope Practiced.” Analysis of the rhetorical 
elements confirmed how the enactment of the consent process was a persuasive 
encounter. (See Table 3, Philosophical Framework.) 
    The third part of the study was a review of metaphors used by participants in the 
109 interviews. In-depth textual discourse analysis was used to identify metaphors 
invoked by participants. Five major categories of metaphor were identified across 
participant groups:  journey, time, hands, faith, and war. The analysis provided a greater 
understanding how hope is cocreated by patients, caregivers, and researchers using 
metaphorical language. Habitus and the concept of agency in decision-making provided a 
framework for recognizing unacknowledged assumptions in metaphorical usage. Once 
made explicit, these assumptions enabled the authors to see how formal and informal 
language have created a powerful incentive for participation in cancer research trials with 
the practice of hope central to the election to participate in research. See Table 4 for 
identification of where specific aims are addressed. 
   The significance of this study is the uncovering of assumptions and examination 
of practices generally taken for granted when hope is invoked in the cancer research 
setting. The author anticipates further contributions to increase understanding of the 
practice of hope and the role hope plays in a patient’s decision to participate in cancer 
research. There is a need for an examination not only of the language, but of the entire 




the associated morbidity and mortality of cancer—are noble. The quest for improved 
outcomes must recognize that hope-for-cure may not be the only outcome hoped for by 
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Table 1  
Participant Characteristics (n=55) 
Characteristic Participants 
Age Range  22–72 
Female No. (%)   30 (55%) 
Race/Ethnicity No. (%)  
Black 2 (4%) 
White 48 (87%) 
Asian 2 (4%) 
Hispanic 1 (2%) 
Native American 2 (4%) 
Patients’ Diagnosis No. (%) (N=25)  
Acute myleogenous leukemia 6 (24%) 
Acute promyleocytic leukemia 1 (4%) 
Chronic lymphocytic leukemia 1 (4%) 
Hodgkins Disease 1 (4%) 
Multiple myeloma 5 (20%) 




Highest Level of Education Completed 
No. (%) 
 
Some high school 2 (4%) 
High school/GED 12 (22%) 
Some college 9 (16%) 
College graduate 12 (22%) 
Some graduate school 1 (2%) 
Graduate degree (includes MDs) 18 (33%) 








Interview by Group 
 Pre 3 mo 1 yr Independent 
Time Point 
Patients n=25 n=21 n=12 NA 
Caregivers n=20 n=15 n=6 NA 







Constructionist-meaning is created via language, and textual review helps 
examine assumptions and taken-for-granted practices like hope (Chapters IV, 
V, VI). 
Methods—a. Discourse analysis of language in use in nursing literature written 
about hope, examining assumptions of published authors in ANS from 1999–
2008 (Chapter IV). 
  b. Discourse analysis of language used by patients, family caregivers, and 
researchers in a quaternary cancer center as transcribed in existing data set of 
109 interviews (Chapter V). 
1. Coding—derived by researcher based on review of the literature on hope and 
her experiences in cancer research. 
2. Refinement of coding—additional coding of participant statements was done 
applying logos, ethos, and pathos to demonstrate how hope is rendered an 
imperative via persuasion in clinical discussions about research. 
Thematic coding was all transcribed for metaphors employed in discussions of 











Specific Aims, Research Questions, Methods, and Where Addressed 
 
AIM  Research Questions Methodology Addressed 
#1 To explore the 
historical discourse of 
hope. 
1. What are the discourses of 
hope that influence how 
people construct hope? 
1. Genealogy of hope, built 
on a review of major 
historical discourses of hope 
as presented in published 
literature. 
1. Chapter IV 
#2 To examine how 
people with cancer 
practice hope relative 
to decision-making 
and cancer research 
participation. 
2. A. How, when, and why 
do patients, family 
members, and researchers 
employ the construct of 
hope? 
 
2. B. What words do patients, 
family members, and 
researchers use as metaphors 
for hope? 
 
2.C.  What words or phrases 
are co-located in discussions 
about hope? 
 
2.D. How is hope practiced 
in a quaternary cancer 
research center? 















2. D.  Discourse Analysis of 
109 interviews 
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Hegemony, Hermeneutics,
and the Heuristic of Hope
Kathleen Shannon Dorcy, MN, RN
Hope has become a commodity, one that society expects those who suffer to invest in
and one that healthcare providers are expected to promote as an outcome. In nursing re-
search, a single hegemonic epistemology/ontology has been implemented through an exclu-
sive hermeneutic (interpretation of data) and has resulted in hope being designated as an
external objective heuristic for those who suffer. Evidence is articulated in this article for
adopting a broader method of analysis and interpretation (genealogy) that can facilitate fuller
apprehension of hope in the human experience of suffering and despair. Key words: con-
structivism, discourse analysis, genealogy, hegemony, hermeneutics, heuristic, hope, ob-
jectivism, phenomenology
MANY RESEARCHERS have studied thephenomenon of hope, the influence it
bears on suffering, and the degree of despair
or hopelessness experienced by patients in
moments of illness and injury. From these for-
mal inquiries into the phenomenon of hop-
ing, a hegemonic theme has emerged, one
that has dominated the published analyses of
hope over time: hope is a positive thing and
people should cultivate hope when coping
with a constellation of physical, emotional,
psychological, or spiritual suffering endured
in episodes of loss, illness, or injury. Hope
has become a commodity, one that society ex-
pects those who suffer to invest in and one
that healthcare providers are expected to pro-
mote as an outcome.
In response to a call by the journal Ad-
vances in Nursing Science (ANS) for critique
and replication of research previously pub-
lished, 3 articles written specifically about
Author Affiliation: Fred Hutchinson Cancer
Research Center, University of Utah, Salt Lake City.
The author thanks Dr Kristin Cloyes, Dr Michael Dorcy,
and Dr Denise Drevdahl. This work was funded in part
by American Cancer Society Research Scholar Award
grant DSCNR-117200.
Corresponding Author: Kathleen Shannon Dorcy,
MN, RN, 1100 Fairview Ave N LF-210, PO Box 19024,
Seattle, WA 98109 (kshannon@fhcrc.org).
hope in the years 1999 to 2009 were re-
viewed. These 3 articles were chosen because
they are representative of the field of health-
care research on the concept of hope and so
provide an opportunity to critique and under-
stand the continuity of the published works
dealing with hope. The articles’ conclusions
about hopewere examined using textual anal-
ysis, so as to identify assumptions and artic-
ulate rhetorical strategies used by the ANS
authors to legitimate their presentations and
their interpretations of the concept of hope.
The purpose of this critique is twofold, first
to provide recognition of the hegemonic ex-
pectations that have established a mandate
in discourse for how research and scientific
inquiry of hope should be done and second
to encourage a broadening of methodological
frameworks employed in nursing science.
ANS STUDIES
In 1999, Forbes1 published a study evalu-
ating 2 different methods (phenomenological
and postpositivist) for evaluation of results rel-
ative to building nursing theory. It was a qual-
itative study of older adults with chronic ill-
ness intended to evaluate methods employed
for the purpose of expanding the conceptual
development of hope.1
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In another study, an Australian researcher,
Turner,2 performed a secondary analysis of
data from her 2002 study of hope in young
people. The original work was a “hermeneu-
tic phenomenological study” that was de-
signed to explore the phenomenon of hope as
perceived by 10 Australian youth. Gadamerian
concepts of openness to meaning and fusion
of the horizons as well as projection, preju-
dice, and fore projection were utilized in the
interpretation of data. Stories of hopewere re-
counted by the youths, recorded, transcribed,
and then analyzed. The reexamination of the
data allowed for the author to gain greater in-
sight into how the very experience of despair
and hopelessness were points where hope
could be “embodied.”2
The third article, by Lohne,3 published in
2008, assumes an analytic framework similar
to the others in employing concept analysis
and a phenomenological foundation for the
purpose of expanding the concept of hope.
The study is qualitative and provides a synthe-
sis of 3 empirical studies on hope within the
context of spinal cord injuries. A conceptual
model was developed and titled “The Battle
Between Hoping and Suffering” and “The
Road of Hope,”illustrating the researcher’s in-
terpretation of the distinction between being
in hope and having hope.3 See Table 1 for
overview of articles.
KEY CONCEPTS
The concepts of hegemony, hermeneutic,
and heuristic are integral to the analysis of the
chosen articles on hope. Hegemony is here
defined as the set of processes by which a
dominant cultural perspective maintains its
dominancewithin a society. In the case of pro-
fessional nursing, cultural dominance is main-
tained through research, publications, and
pedagogical expectations. These provide a
consistent and largely unchallenged perspec-
tive of what constitutes quality research.
Hermeneutics is here defined generally
as the interpretation of meaning, not only
in linguistic analysis but more broadly in
cultural and ontological assignations of mean-
ing. Nursing research has generally affirmed
a hermeneutic stance that investigators can
sufficiently “bracket” themselves as distant
from the data and so assure an “objective”
conclusion.
The final concept, heuristic, is used as
a noun and describes a process/method
wherein an individual solves a problem or re-
solves a situation. In the analysis that follows,
a presentationwill bemade that demonstrates
how a single hegemonic epistemology/
ontology has been implemented through
an exclusive hermeneutic (interpretation
of data) and has resulted in hope being
designated as an external objective heuristic
for those who suffer.
HOPE
Within an objectivist epistemology, hope
becomes an artifact or an object.With hope as
an external reality, power to access hope rests
with those who “know the way” and grants
those who know the truth of hope a kind of
ultimate power. Thus, the researcher can as-
sume a position of power to provide hope or
guide others to hope. This is particularly true
when the researcher is within a clinical set-
ting. The objectivist framework of research is
capable of reducing abundant and sometimes
conflicted semiotic data into a single univer-
sal concept.
Some of the questions to consider in this re-
view of ANS published discourses about hope
are as follows: (1) How is hope conceptual-
ized? (2) Are there existential, propositional,
or value assumptions integral to the author’s
premise? (3) What is the explicit or implicit
hermeneutics (interpretation of meaning) ap-
plied to the data? (4) Can hope be defined in
a universal manner that reduces all hope to a
singular truth? To aid this effort, a genealog-
ical review will synthesize selected publica-
tions from the genre of healthcare providers’
research efforts and some selective construc-
tions of hope as viewed historically.
Genealogical here means the intensely
comprehensive synthesis of the origins and
46
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evolutions of “truths” taken for granted and
assumed to have a universally static value.
Genealogy challenges the historical linear
progression of how meaning is transported
through time and acknowledges the complex
mosaic from influences of politics, religion,
theology, and economics on the construction
of meaning. Genealogy, as distinct from a con-
cept analysis, sees multiplicity in meaning as
opposed to a single universally applicable def-
inition necessary for the formulaic compre-
hension of a concept.4
SELECTED GENEALOGY OF HOPE
To draw conclusions about how hope is
present within the clinical context of health-
care, it is first necessary to explore the com-
plex and often-complicated aspects that the
notion of hope carries through time and con-
text, namely, hope as a benefit versus hope as
a curse. A quest for origins suggests a dualis-
tic, even a contradictory, nature of hope.4,5
Hope is an old term, richly imbued with
mythological and theological associations. As
recorded in accounts of the Greek mythol-
ogy, hope was one of the consignees of Pan-
dora’s box, with hope, or elpis, as the last of
the contents of the opened jar or box (de-
pending on the version of the myth). Pandora
had received the box from Zeus, or Hermes,
with the warning to never open it. Curiosity
got the best of Pandora, however, and upon
her opening of the lid, evil and misfortunes
were unleashed upon the world’s population.
Pandora then closed the box and left hope
trapped inside. One version of the myth has
an intervening time of trials and tribulations
for the world before Pandora returned to re-
open the box and “out fluttered hope.” One
interpretation of this action asserts that the
final release of hope was symbolic of better
times promised in the midst of hardships. An-
other interpretation, for instance that of Niet-
zsche, is that elpis, hope, should be the worst
of all evils, something that is representative of
terrifying foreknowledge. Pandora saved the
world by preventing its earlier escape out of
the box. Clearly, 2 divergent conceptualiza-
tions of hope emerge early on, dependent on
the version of the myth conveyed.6
The discourse of hope in the Bible gener-
ally is distinct in its use whether in the Old
or the New Testament.7 The Hebrew word
Qoh for hope implies a future orientation or
expectation, and this expectation is closely
linkedwith trust and confidence in the future.
Also from the Hebrew, piel is a verb, mean-
ing “quiet waiting” or “perseverance” or “to
expect with tenseness.”Yet another variation
in Hebrew is qwh pi, which means “to hope,”
“to expect or towait upon.”7,8 In the NewTes-
tament, there is a transition to the word hope
that implies transformation and steadfast en-
durance. The New Testament employs hop-
ing as a verb to represent redemption from
suffering and the transcendence of evil and
threats of persecution. Hope as a noun in
the New Testament signifies a covenant, or
a promise between the people and the God
of salvation. This covenant has imbricated el-
ements of waiting, trust, faith, confidence, ex-
pectation, and motivation.9
HOPE IN MODERN DISCOURSE
Hope has been described in more recent
times as a construct that provides comfort,
encouragement, and an ability to look to-
ward a more positive future. In discussions
regarding health, hope is derived from the
premise that hoping is integral to how peo-
ple clarify, prioritize, and affirm their choices
within healthcare. Several studies have identi-
fied hope as a resource for coping with can-
cer, one that provides the patient with strate-
gies for managing the disease and engaging in
social support.10–13
Hope has been identified as a key activ-
ity in coping, resilience, empowered self-care,
and perceived quality of life in patients with
cancer.14–19 Several studies have drawn direct
links between patients’ faith experiences and
connections to God as correlative with the
experience of hope.17,20–24 The association of
hope with spirituality and religion is a strong
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cultural and literary tradition within Western
Judea-Christian cultural groups. This relation-
ship between hope and spirituality can be
useful in determining how hope is employed
within a Judea-Christian context. This con-
text, however, can provide a barrier to hope
for those outside this Westernized linguistic
tradition. Insight into how people have used
hope through time and how cultures have, in
some instances, reified hope into a positive
attribute one should possess is a critical ele-
ment of a comprehensive analysis.
HOPE AS AN INTERPERSONAL
INTERACTION
The dialogue patients have with care
providers about disease progression, the low
likelihood of survival, and the possibility of
impending death are often laced with nu-
meric representations of chances for survival.
The dissemination of statistical information
has been correlated with the increase of hope
in patients with cancer. The use of survival
statistics in conferences between patients and
providers has been examined and found to be
a complex issue as patients both desire the
facts in numeric format and resent the impli-
cations contained in the numeric risk state-
ments. Despite feelings of resentment, some
patients report taking comfort in the statis-
tics, even when a 5% cure rate was predicted.
The translation of this, the tiniest chance of
survival, gives individuals an invitation for en-
gaging in the practice of hoping so as to be
among those who could comprise the small
survival statistic.20
The literature affirms that decisions to par-
ticipate in clinical research are influenced by
patients’ hope and hope is created in the
context of shared communication in many
forms.15,20–24 In surveying patients about a re-
cent media campaign for a new chemothera-
peutic agent, researchers found that viewing
media had an effect on patients’ awareness of
self-care options and provided opportunities
to foster hope. The Internet has become an-
other source of social support and informa-
tion seeking.
MEASURING HOPE
The Herth Hope Scale, introduced in 1989
and later shortened to the Herth Hope Index,
examined the relationship between levels of
hope and levels of coping response in adult
oncology patients receiving chemotherapy.
Herth17–19 found that individuals with self-
identified strong religious faith had a higher
level of hope and coping response than those
without faith or who reported “weak faith.”
Most significantly, the author asserted that
hope is important in the life of people with
cancer. The HHI is built upon a premise of fa-
miliarity with religious and cultural represen-
tations of hope and demonstrates another ex-
ample of inherent existential, propositional,
and value assumptions. This integration with
religious discourse is an element of intertextu-
ality and continuity, which demonstrates how
hope enactment is coauthorized by the so-




Scientific publications, considered as texts,
are genres that inculcate the continuity of
current paradigms of scientific thought. The
inclusion and attribution of other voices
demonstrate the concept of intertextuality.4
The claims made in texts are often founded
on assumptions that, though not explicitly
stated, represent strong components of mean-
ing. A value assumption present throughout
all the ANS texts is that hope is a good thing
and that people should hope. The existential
assumption in all the articles is that hope ex-
ists as a positive phenomenon. The proposi-
tional assumptions are that hope can serve as
the heuristic to suffering and that interview
data corresponds exactly with reality.25 See
Table 2 for more details.
Intertextuality involves the recognition of
explicitly named and cited references as well
as recognition of other references present im-
plicitly, unstated, or not cited. In the 3 ANS
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Table 2. Author assumptions
Forbes1 (1999) Turner2 (2007) Lohne3 (2008)
Existential
assumptions
Hope exists as a positive
phenomenon.
Hope exists as a positive
phenomenon.




(what is, can, or













Hope is future oriented. Hope is future oriented. Hope is future oriented.
Hope is helpful to
chronically ill people.
Hope is helpful for young
people confronted by
loss and grief.
Hope is helpful and
cyclic for people with
spinal cord injury.
Value assumptions
(what is good or
desirable)
People should hope. People should hope. People should hope.
Hope is important. Hope is important. Hope is important.
Depth of data is good.
Saving time is good.






articles, the texts referenced are constitutive
of the context of a recognizable discourse on
hope over time. Implicit intertextuality can
be seen in the themes of hope as a heuris-
tic to suffering, in the method of analysis, and
in the hermeneutics utilized as grounded the-
ory, objectifying or reifying hope. Each author
employed phenomenology as the theoretical
framework for the investigations into hope.
Notably, none of the authors referenced the
same philosophers. Frankl,26 an existential
psychiatrist, is cited by Turner2 and Lohne3
but not by Forbes.1 A list of explicit shared
references can be found in Table 3.
Legitimation is an analytic tool and can
be useful in the examination of texts as it
helps specify how authors legitimate their
Table 3. Explicit shared references
Forbes1 (1999) Turner2 (2007) Lohne3 (2008)
Morse and Dobernick27 Yes No Yes
Dufault and Martocchio10 No Yes Yes
Erikson28,29 No Yes Yes
Lynch30 No Yes Yes
Frankl26 No Yes Yes
findings. The strategies for legitimation ac-
cording to Fairclough’s categorization are as
follows: authorization, rationalization, moral
evaluation, and mythopoeis. Authorization is
the referencing of the authority of tradition
by custom or law. Rationalization is refer-
encing the utility of institutionalized actions
and knowledge as constructed by cultures
to recognize cognitive validity. Moral eval-
uation references legitimation by value sys-
tems, and myothopoesis references legitma-
tion conveyed through narratives of various
kinds.25(p98)
Each of the ANS authors shared a tradi-
tion of implementing theory generation as
a method that produces reliable authorita-
tive truth, thus providing legitimation by
51
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Table 4. Legitimization
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authorization. Rationalization was established
with the formal citation of established experts
in the field and the linking of those experts
to cognitive validity. Moral evaluation was in-
voked by the explicit message that hope is
good and peoplewho suffer should hope. The
use of narrative data and the author’s master-
ful interpretation of those narratives as truth
is one way that legitimation by mythopoesis
was established by each author.25 See Table 4
for more details.
The articles themselves are representa-
tive of culturally distinct voices. Forbes1 is
an American, Turner2 is an Australian, and
Lohne3 is Norwegian. Forbes writes while she
was an assistant professor at the University
of Wisconsin-Milwaukee in 1999, where the
prevalent hegemonic voice of academic re-
search at the time was shifting from objec-
tivism as a research epistemology to construc-
tivism. Her research was about comparing the
2 epistemologies andmethods to ascertain dif-
ference in theory generation for hope. The
comparison of 2 methods in theory building
was done with a phenomenological method
of interview involving chronically ill, older
people. The alternative method of concept
mapping was accomplished by using a com-
puter program to analyze the narratives of a
group process.1
According to Forbes,1 the differing meth-
ods delivered similar results and were found
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to be consistent with the findings in the pio-
neering work of Morse and Doberneck27 who
identified the themes of uncertainty, endur-
ing, and suffering. The epistemological model
in Forbes1 is still objectivism, and the inquiry
seeks to define hope as a unitary, universal
truth that exists external to the individuals.
In keeping with phenomenological ontology,
it endeavors to reveal the “lived experience
of hope” in older people with chronic illness
(see Table 1).
Turner’s study2 engages in a “reimmersion
in existing data” to gain greater insight into
hope as seen through the eyes of 10 young
Australians. In this work, the author makes a
powerful point that the stories of hope from
the youth were often articulated through ex-
periences of intense suffering and loss. This
poignant interplay between hope and suffer-
ing is in continuity with the historical ge-
nealogy of hope where hope is employed
to transcend or transform situations of pro-
found suffering and despair.2 The youths in
Turner’s study construct hope from the core
of their own beings, similar to what Frankl
observes of hope, “rising above the suffer-
ing of the moment.”26(p29) Concluding com-
ments of the author suggest that hope is the
actual process whereby suffering can be “ap-
prehended.”A crucial element in this author’s
work different from the other studies from
ANS is the view of hope as internal to the
individual, an experience that can be shared
between people and not some thing, not an
object of reified external reality with a single
unitary meaning.2 See Table 1 for full study
summary.
The third author, Lohne,3 is a widely pub-
lished researcher and educator in Norway.
Her work also focuses on understanding hope
in the context of suffering after incidences
of spinal cord injury. The findings from
her longitudinal study are consistent with
Danish researchers Kylma¨ and Vehvila¨inen-
Julkunen.31 Their meta-analysis of literature
relative to hope in nursing concluded that
most of the research on the topic of hope
has been grounded in a positivist (objective)
paradigm.31
Lohne’s philosophical framework com-
bines existential phenomenology and a use
of a “hermeneutical circle” as the tool for
interpretation. In this interpretative process,
the author specifies that understanding of the
data grows from the naive to a deeper com-
prehension of the whole text and its individ-
ual components. Lohne cites Ricoeur’s con-
cept of distanciation as a process whereby
the interpreter approaches the text without
consideration of the individual participant’s
intentions or intent.32 “During this process of
understanding, the text is freed from its origi-
nal context and given a life of its own.”3(p242)
Lohne’s formulation of hope is influenced by
the philosophy of Gabriel Marcel for whom
the concept of being should be understood
as a internal activity, one derived from act of
existence.33(p246) Lohne’s conclusions clearly
identify a distinction between being in hope
and having hope. (See Table 1 for full study
summary.)
DISCUSSION
In Forbes’s study, the theoretical frame-
work referenced is existential or phenomeno-
logical. The study employs 2 methods of as-
sessing the development of hope with older
adults: phenomenological individual inter-
view analysis and a comparison with a group
interview utilizing Ward’s hierarchical clus-
ter analysis. Fundamentally, theory generation
regarding hope was the explicit goal of the
study. Forbes’s findings are an attempt to ar-
rive at a universal definition of hope. Ulti-
mately, hope is a heuristic for coping with the
limitations of aging and chronic illness.1
In her 2002 study, Turner2 found that
hope was crucial in the lives of Australian
youth who suffered traumatic life experi-
ences. Hope was seen as something that facili-
tated coping with the pain, as well as allowing
for the full “apprehension of the suffering.”
The existential assumptions in her work are
also that hope fulfills a positive, good role in
the lives of those who suffer. After reimmer-
sion in her original research, Turner2 stated
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that at this juncture she is abandoning her
search for a universal definition of hope. Her
theoretical framework is phenomenological.
The 2008work by Lohne3 is also rooted in a
phenomenological and an existential theoret-
ical framework. This work is concerned with
theory generation and demonstrating concur-
rence with previous works on hope. The con-
tinuities evident in her article build exactly
upon the premises and methodology of other
grounded theorists and could be said to show
fidelity with this shared method. Being on the
road to hope is contrasted with being on the
road to death. Hope is a signifier for life in
this work and serves as heuristic to the pro-
cess of suffering and the “vicious cycle” be-
tween despair and will and faith. The rela-
tionship of hope to matters of faith is clearly
demonstrated as a continuity with Lohne’s
work.3
In schools of nursing, concept analysis is
commonly taught as a step-by-stepmethod for
increasing the “maturity of a concept”to con-
tribute to the generation of theory. Steps guid-
ing concept analysis are concept delineation,
concept comparison, concept clarification,
concept correction, and concept identifica-
tion. In the case of hope, this kind of anal-
ysis and hermeneutic includes the premise
that in establishing the maturity of the con-
cept, the researcher is “giving voice” to the
patient’s hope. Utilization of the metaphor of
giving voice is an explicit example of how
hope is seen as something that is able to be
handed to another. Hope as a thing and hope
as experience are themes imbricated within
the general discourse on hope. Also, inher-
ent in the objectivist’s interpretation of hope
is that the assumption that the words of in-
terview data are a precise representation of
objective reality. This assumption of objec-
tive reality in the interview data creates cer-
titude relative to the researchers’ interpreta-
tion. It is as if the final assessment, analysis,
and conclusions of the data have a unitary
meaning, one stated by the participants of the
study and then precisely represented by the
researcher.33,34
The works on hope in ANS have con-
tributed significantly to the study of the phe-
nomena of hope. Each embodieswhat Kuhn35
has classified as “normal science,”whereby a
discipline creates a matrix of practices that
are considered paradigms for replicating and
proving mature science. Theory generation is
what nursing has chosen as its exemplar for
research in the social sciences, and the ANS
authors are expert at this implementation of
method and interpretation. But, as Kuhn32
speaks of revolutionary science as totally dis-
tinct from normal science, perhaps it is time
to move into a new paradigm of practice for
future investigations into hope.
Current methods for understanding hope
are hegemonic in academic analyses of
hope within the genre of nursing literature.
Hope is assumed to be a positive thing, and
people should endeavor to have hope or to
encourage others in it. The hermeneutics in-
volved in deriving meaning from data also de-
serves a second look. Researchers now must
acknowledge their own personal presence as
it influences the posing of the research ques-
tion, the collection of data, and the interpre-
tation of data.
Nursing research has progressed from the
early 1990s when qualitative methods argued
for the investigator to bracket oneself and
to strive for the goals of authenticity or fi-
delity to the spoken words of interviewees,
essentially an objectivist version of interpre-
tive studies. Most of the research on hope is
interwoven with an objectivist epistemology/
ontology that relegates meaning to the objec-
tive reality. More recently, Eliott and Olver14
have studied hope, using discourse analysis
as the method for analyzing the words of pa-
tients speaking about end-of-life decisionmak-
ing. This linguistic framework systematically
allows for the analysis of hope both as a verb
and as a noun and demonstrates how language
is powerfully nuanced in the act of hoping.
Eliott and Olver’s14 interpretive process al-
lows for meaning to be explored in new ways
rather than only in the paradigm of concept
analysis and theory generation.
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ALTERNATIVE TO CONCEPTUALIZING
HOPE
Eliott and Olver14 posit that hope is a
phenomenon constructed in the words and
shared dialogue of people, as opposed to a re-
ality that exists independently, outside of the
of the individual or the researcher. Their an-
alytical premise is shaped by the notion that
language is not a neutral, transparent descrip-
tion of the objective world. Rather, it is cul-
turally contextual explication of the speaker’s
intentions. The authors assert several charac-
teristics of hope. It is both objective and sub-
jective; it is a burden and a resource. It may
be a tool for evaluating situations, an inspira-
tion for action, or a reason for inaction. It is
present or future oriented and may be at once
both vulnerable and enduring.14
Eliott and Olver14 suggest that hope should
be viewed as taxonomy rather than as an ex-
ternally derived, unidimensional definition of
an objective concept. They privilege the spo-
ken word as the surest explication of the indi-
vidual’s notion of hope. They assert that the
objective definitions and attempts to measure
hope in various scales limit hope, decreas-
ing hope’s relevance for people. Finally, the
authors conclude that patients do not differ-
entiate between unrealistic hope and realis-
tic hope, demonstrating a multiplicity of di-
mensions of hope and the need to have a
broad range of meanings in order for hope to
function.14
CONCLUSION
It is important to understand that what
is critiqued here is not the findings of the
authors in ANS but rather the unchallenged
processes of professional research practices
that assure the continuities of normal sci-
ence alone. While normal science is valuable,
nursing as a profession needs to broaden the
methodological approaches employed in in-
terpreting hope to allow for recognition of the
vast implications hope has on individuals and
professional practice. Providers are not sepa-
rate or disengaged from the process by which
hope is “created” in the lives of patients and
their families.
The commodification of hope has played
a significant role in the marketing of West-
ern healthcare ordaining hope as a positive
force in the face of suffering. The use of
hope as a commodity reinforces how valu-
able hope is as concept for people in gen-
eral. Hope sells everything from new inven-
tions to cancer centers and the fund drives
that support these endeavors. Hope as a com-
modity is an omnipresent but unexamined
presence in the daily practice of healthcare.
Providers are deeply invested in hope as it in-
spires providers and comforts providers who
work with those who suffer and those who
are in despair.
It is not the intention of this author either
to diminish hope or to impede the hoping
process for patients or for care providers. In-
stead, this is a call for recognition of the hege-
monic expectation mandated for patients and
family members by society and translated by
care providers into daily practice. Hope is of-
ten a scripted performance that can in fact
become coercive when an expectation exists
for people with life-threatening illnesses or in-
juries to keep trying and to not give up hope.
In this situation, hope can become merely a
heuristic for suffering and despair, reduced
to a coping mechanism. Moving beyond cur-
rent approaches to a broader comprehension,
hope may be seen as a potentially powerful
and more varied opportunity for those who
suffer and who are in despair.
Providers have dichotomized the context
of hope in many situations as life or death.
This operative dichotomy leaves those who
suffer illness with a deeper sense of despair
as they are labeled noncompliant or dysfunc-
tional when the choices made do not agree
with what providers judge to be the best or
the most hopeful option for patients. In the
words of Gabriel Marcel, “. . . there can strictly
speaking be no hope except when the temp-
tation to despair exists.”36(p36) It is within
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profound suffering and despair that hope is
enacted. We do not need a unitary definition
of hope. In confronting the vagaries of human
suffering and despair, the practice of hope
must not be limited. Further explorations into
the meaning and performance of hope must
be open to the complexities existing within
the experience of human hopelessness.
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THE HABITUS OF HOPE: THE HOPE IMPERATIVE 
 
Abstract 
  Hope has been promoted as an integral component in the care of cancer patients. 
Within the nursing literature, hope has been reified as an objectified singular reality that 
can be measured and promoted for patients. Yet hope may be also be a constructed, 
coercive component in clinical decision-making in which providers are complicit in 
wielding hopeful influence. Patients, family members, and researchers share a habitus of 
hope defined contextually and reflexively by language.  
 Hope is a powerful multidimensional social practice, and nurses and researchers 
need to recognize how hope can be used to coerce people into opting to follow 
recommended courses of care or research.  Discourse in cancer centers between patients, 
nurses, and researchers reinforces the habitus of hope, or the hope imperative. 
Examination of the discourse of cancer and hope reveal ethical implications for the 
support of patients and family members relative to cancer research and decision-making. 
As an expectation of cancer care providers and researchers, hope represents a political 
and social power differential. In choosing options for cancer care, patients may have no 
other choice than to subscribe to the hope imperative.   
 




   The American Cancer Society reports a combined cancer incidence rate of 3,937, 
and a mortality rate of 1,684.5 per 100,000 in the United States (ACS, 2010). These 
numbers represent the statistical count of people who have had to face a diagnosis of 
cancer and who, together with their family members and physicians, have had to make 
decisions relative to treatment and research interventions. Cancer centers recognize the 
power of the word hope so well that it even appears in the name of some cancer centers 
(i.e., City of Hope in Duarte, California; Patrick Dempsey Center for Hope and Healing 
in Lewiston, Maine; and Florida Cancer Institute–New Hope in eight locations in 
Florida). Hope is even more widely employed in the branding effort attached to cancer 
treatment centers.  
Hope is a word widely employed within the context of cancer care decision-
making for patients and family members.  “Hope is all I have left. . .” (A3) These words 
of one cancer patient, explaining why he opted to enroll in an early-phase cancer clinical 
trial, are not untypical of the discourse appealing to a shared understanding of hope heard 
within the clinical setting. This paper calls for an exploration of how cancer care 
discourses are linked inextricably to the discourses of hope.  This overlapping of 
discourses may result in unintended consequences, including coercion for people who 
consent to participate in clinical research or interventions for prolonged aggressive 
disease.  
Days after surgery for a malignant brain tumor, Senator Edward Kennedy greeted 
the press with a “thumbs up” gesture when asked how he was doing. At the same general 
time, his wife sent an email to friends and family saying that although the Senator was 
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learning to deal with fatigue, “the news is all positive and encouraging” (Altman, 2008). 
Both Senator Kennedy and his wife demonstrated what might be called the “hope 
imperative,” a cultural expectation ingrained in Americans to “look at the bright side.” 
   Barbara Ehrenreich (2009) described this cultural phenomenon as positivity. 
“Positivity,” she writes, “is not so much our condition . . . as it is our ideology—the way 
we explain the world and think we ought to function within it” (p. 4). For her, the 
experience of being “recruited” into positivity happened when she was diagnosed with 
breast cancer. Everywhere she encountered messages that commanded she “accept her 
cancer” and “see it as a gift.” She vehemently disagreed with this command performance 
of positivity. She asserted that the social mandate of positive optimism and “fake cheer” 
requires a patient’s denial of feelings of anger and fear. Additionally, she felt the only 
benefit of positivity is that it provides a “great convenience for health workers” 
(Ehrenreich, 2009, p. 41). 
 These examples highlight the deep desire Americans have to be positive or to be 
perceived as being positive. Cancer patients are regularly confronted with the hope 
imperative: the expectation that to be successful in the medical system, they need to be 
willing to be positive and try to achieve a successful outcome—one defined as a cure or 
at least an amelioration of the cancer. Patients’ contributions to their own care and to the 
healthcare system are generally as cultivators of positivity, with “hope” as the talisman. 
Some recent literature has commented on “unrealistic optimism in early phase clinical 
trials” (Jansen et al., 2011) and associated this phenomenon with patients’ belief that 
“expressing hope and having an optimistic attitude would actually improve the likelihood 
that they would experience a therapeutic benefit” (Sulmassy, 2010, p. 3708). 
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Interestingly, within this work the researchers appeared to blame the patients themselves 
for harboring “unrealistic optimism” and offered little insight into the influence 
researchers and cancer care providers have on these expressions of optimism.  
 
Decision-Making 
 Federal regulations have long offered a strict formula for how consent should be 
offered and confirmed for participation in research studies (CFR 45 § 16:124). Given that 
care providers have a federal mandate as well as an ethical obligation to assure all 
decision-making is free and not coerced, informed consent and the influence of hope in 
cancer care decision-making need to be more fully understood.  
There is a gap in current literature regarding decision-making and the role hope 
plays for cancer patients who are trying to decide whether to enroll in clinical trials. The 
very paradigm of decision-making bears further research, as some investigators have 
shown that patients opting for surgery for advanced cancers saw the surgery more as a 
“next step” rather than a decision for or against something (Ferrell et al., 2003). In our 
efforts to assure ethically sound decision-making, perhaps we have been over-zealous in 
our determinations of how we should frame options for cancer care and research. We 
need to ascertain what best supports patients and families in choosing options of care. 
Early-phase research should be reevaluated to determine how mandatory regulatory 
decision-making guidelines are implemented. 
 




  Hope is a word quite commonly used as healthcare personnel dialogue with 
patients who have been diagnosed with cancer. As a concept, hope obviously helps 
people who are dealing with hardship, loss, fear, anxiety, and pain. As an operative 
concept in the lives of cancer patients, hope has been investigated by many and found to 
be significant for people living with cancer and undergoing cancer treatment (Caocci et 
al., 2006; Dickerson, Boehmke, Ogle, & Brown, 2006; Dufault & Martocchio, 1985; 
Ebright & Lyons, 2002; Eliott & Olver, 2002, 2006; Ersek, 1992;  Herth, 1989, 1992, 
2000; Huizinga, Sleijfer, van de Wiel, & van der Graff, 1999; Kylma & Vehvilainen-
Julune, 1997; Nowotny, 1989; Pentz et al., 2002; Rusteon & Wiklund, 2000;  Saleh & 
Brockopp, 2001; Schutta & Burnett, 2000; Thorne, Hislop, Kuo, & Armstrong, 2006). At 
an extreme end of the spectrum, an author critiqued nurses who seek to “engender hope 
in patients” as lacking evidence from randomized clinical trials (Lipscomb, 2007). 
   Hope has been presented as a method of coping (Dufault & Martocchio, 1985; 
Herth, 2000; Menninger, 1959; Lynch, 1965; Snyder et al.,  2002, 2004); as a theological 
precept (Aquinas, 1920; Moltman, 1993; Luther, 2005); as a literary theme (Dickinson, 
1993; Donne, 2001; Shakespeare, 1998); as a psychological component for coping with 
suffering (Frankl, 1963; Herth, 1989, 1992, 2000; Lynch, 1965; Menninger, 1959; Morse 
& Doberneck, 1995; Snyder et al., 2002); and as a philosophical framework (Aquinas, 
1920; Athanassakis, 1983; Bloch, 1986; Nietzsche, 1996; Voltaire, 1924). Hope has also 
been considered a source of motivation associated with the successful achievement of life 
goals, such as winning at sporting events, being accepted  into college, and finding 
success in school (Snyder, 2000; Snyder et al., 2002; Valle, 2006). This array of 
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constructions of hope across time and genres has clearly had a profound effect in 
informing and shaping societal and individual concepts of hope. 
  “Hope” is understood in the broad variety of ways people talk about it (Eliott & 
Olver, 2002). Talking is discourse, and discourse analysis is defined as  “an examination 
of language in use” (Schwandt, 2001, p. 57). Considering discourse as an element of 
habitus (Bourdieu, 1984) helps show how multiple meanings are created and how shared 
meanings are developed in usage. 
 
Habitus 
 Pierre Bourdieu (1984) used the term habitus to refer to the socially acquired, 
embodied systems of dispositions or predispositions that individuals share. Bourdieu 
borrowed the word habitus from the Latin, in which it means a pattern, a characteristic, a 
condition, or a quality of the individual. Bourdieu regarded personal choices or 
preferences as neither random nor linear components of an individual’s life. For 
Bourdieu, the tapestry of human existence was a blend of personal agency greatly 
influenced by culturally accessible experiences and choices available to each person in 
the course of one’s life.  
   Habitus is not only about moral socialization; it is about personal inclinations, 
tendencies, and propensities in opinions, behavior, decorum, and practices within 
different historical and cultural settings. Important for understanding how these social 
and cultural factors influence individual decision-making or consent process, Bourdieu 
carefully avoided determinism or essentialism as philosophical notions, because those 
notions leave humans passive and powerless in reflexive responses to stimuli. Change is 
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not a possibility if one’s responses are programmed by essentialist determinism (habits in 
the narrow sense), and there is no free will or authentic autonomous choice.  
    In the context of the current discussion, it is the ability to make choices while 
remaining engaged with the researchers and with societal norms that define what it means 
to be a “good patient.”  This constitutes the habitus of hope.  The word hope is part of a 
shared cultural discourse, and as an idea it is part of a socially constructed reality—a 
cooperative process—not one that takes place in a vacuum. People are raised in a social 
milieu where they learn to comprehend within the give and take of discourse such social 
practices as “fitting in.”  
Both cancer patients and researchers engage in a reflexive dialogue. In addition to 
the community or global overview of dominant discourse, it is also necessary to 
scrutinize the micro or less official uses of power, such as those conveyed by tone, word 
choice, hesitation, pronoun use, and rhetorical style (Wetherell, Taylor, & Yates, 2001). 
Within these linguistic elements is a considerable bias of Westernized dominant culture 
that assumes what hope should look like. 
Hope is most often an objectified thing, assumed to have a singular definition—a 
process that can be linked to Judeo-Christian theological-philosophical precepts. The 
discourse of cancer research for both patients and physicians is shaped by the desire to 
cure cancer. A habitus of hope—the cradle of the hope imperative—is reinforced by 
society’s avoidance of speaking of death and a strong societal bias that cure is the 
ultimate goal of cancer care. Hope as a co-creation between cancer patients, their family 
members, and researchers can be seen in quotes from each of the patients, family 
members, and physician researchers involved in the study. 




 The present study relied on a discursive (or close textual) analysis of secondary 
interview data in which the influence of hope on decision-making for cancer research 
participation were explored. All participants were identified within a large quaternary 
center in the northwestern United States.  The original sample included 25 people 
diagnosed with a hematologic malignancy, each of whom had consented to participate in 
a Phase II hematopoietic cell transplant (HCT). Twenty additional subjects included in 
the study were family caregivers designated by the patients to be interviewed. Ten more 
subjects were physicians who oversaw care of HCT patients and participated in consent 
conferences with patients and their family members (see Table 9). A waiver of consent 
was granted by the Institutional Review Board (IRB) to allow for the secondary analysis 
of transcripts. The original study was explained to all participants; each signed a written 
consent form and was given copies of the consent form.  
  The secondary analysis included 109 transcripts of semistructured interviews that 
were conducted at three time points during a year. The patients and designated caregivers 
were interviewed immediately after consenting to the Phase II HCT protocol, again at 
eighty days post-HCT, and finally at 1 year post-HCT. Hyperreseach© software was used 
to review and code transcripts. Interviews were examined using discourse analysis and 
the elements described above; researchers specifically looked for how the language of 
hope was articulated and nuanced. Quotes from participants were identified and coded to 
elucidate where and how the language of hope occurred in the dialogue of subjects 
relative to discussions of how patients and their families decided to participate in clinical 
research. The following codes were applied to statements in the transcribed interviews: 
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Genealogy, Hope as Noun, Hope as Verb, Hope as Practiced, Active Voice, Passive 
Voice, and Metaphors. 
 After the codes were applied, it became clear that the codes were too limited and 
static to fully capture the dynamics of the decision-making process. Though mandated by 
federal policies, the informed consent conference facilitates an encounter between the 
researcher and patients and their family members; it is a rhetorical event that socially and 
dynamically aligns speakers and hearers in a process of persuasion. The interactive 
process includes the components of reasoning, conveying value, and compassion. 
Although the informed consent process retains some of the aims of traditional rhetorical 
practice, such as teaching or instructing, this didactic aim can easily be subordinated to 
another rhetorical aim—that of moving or persuading. The elements of logos (logic of the 
argument), ethos (trustworthiness or credibility of the researcher), and pathos (emotions 
of the audience) have been used to further refine and integrate the data in order to capture 
the dynamic interplay of the decision-making performance. Use of logos, ethos, and 
pathos confirmed that the enactment of decision-making for participation in cancer 
research is a persuasive encounter.  
 
Rhetorical Analysis  
 
Rhetoric 
  The general framework of rhetoric was chosen in order to analyze the dynamics 
of discourse contained in the transcripts of the series of interviews.  Rhetoric is 
reproduced and reinforced within the cultural milieu as a durable disposition. Living in a 
culture, learning the language, and experiencing life over time creates a recognized 
reality that is socially accessible to individuals as they negotiate daily life and engage 
   
	  
66	  
with others in the community. Critical analysis of language use can only be done with an 
adequate comprehension of constitutive social power. In the study of discourses on hope, 
it is imperative to understand what privileged certain discourses and instilled them with 
power. For instance, in the early Christian church, priests had preferential access to 
written texts and scriptures; that access resulted in a discourse shaped by a religious and 
theological set of actors whose agency and cultural context allowed for the employment 
and interpretation of the concept of hope within a broad context of a class of people beset 
by poverty and suffering. For cancer patients today, the historic discourse of cancer and 
how it is to be treated has been transformed within the context of an intensely detailed 
medical model for intervention. The power, then, is within the hands of researchers and 
those who finance that research.   
 Rhetoric, defined as “as the faculty of observing in any given situation the 
available means of persuasion”	  (Rhys, 1961, p. 9), is not generally a concept applied to 
the analysis of patient decision-making. But rhetorical analyses can help illuminate the 
insinuation of coercion introduced by the hope imperative present in recruitment of 
patients for cancer clinical research participation.  
 
Portrayal of Persuasion 
 The patients who were enrolled in the study had hematologic malignancies and had 
decided themselves or had been referred by their primary oncologists to seek an HCT. All 
the HCT protocols were Phase II research protocols; some had as few as 4 patients in the 
protocol prior to the study participants’ enrollment. The research protocols represented 
early-stage research designed to evaluate safety. 	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Reasoning or Logos 
 The principle of informed consent uses logos as the key marker for a participant’s 
cognitive awareness and understanding of implications of research participation. Within 
the sample, 92% of the patients and 75% of the family caregivers stated that they had 
decided that they would participate in any clinical trials that were offered before they 
arrived at the cancer center and before the consent conferences or reading of consent 
forms (Shannon Dorcy & Drevdahl, 2011). The decision to participate before the 
“consent conference” was held indicates the patients’ a priori placing of hope in the 
center’s research offerings. 
 Patients’ comments made poignantly clear how well they had come to a cognitive 
understanding of the research process. The wife of patient who had traveled from another 
country for care at the center said, “No, it was not a decision. I mean, do you want to live 
or do you want to die? Well, I think we both vote that he live, and this is the only way 
that was a possibility. So there was no need for discussion” (Participant 19B). One patient 
reasoned, “If I relapse, I’m the same I would have been had I not gone through this. 
Somebody’s got to be in the 20–30% range, and I am one of them” (Participant 5A). A 
female patient stated, “I couldn’t leave myself with any regrets that there was something 
that I didn’t try for a cure. . . . I couldn’t have any regrets, even though the numbers 
didn’t look that great” (Participant 9A).  
 Participants expressed some degree of clarity about the risks they were facing 
with the hematological diagnoses they had received and they understood the potential 
risks and possible benefits they might have if they decided to participate in clinical 
research trials. One physician summed up several of the patient/family experiences by 
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saying, “[It’s] a terminal disease, one they could have lived with for several months or a 
year or two before they would succumb to it. . . . .So they come here with the hope of 
being cured” (Participant MD 2).  
 
Reputation or Ethos 
 Part of the equation for evaluating the success of the persuasion in the consent 
process is how well the hearers—the patients and families in this case—perceive the 
credibility or goodness of the speaker. Many of the patients (64%) and family members 
(50%) articulated how important it was to them to know of the national reputation and 
ranking of the research center (Shannon Dorcy & Drevdahl, 2011). Patients who had 
been diagnosed with aggressive diseases like acute myelogenous leukemia (AML) and 
who had been referred to the center within days of the diagnosis spoke of trusting the 
referring center and the credibility of their hometown physician. Other patients had done 
national searches in the literature and consulted with other agencies to seek out what 
could be termed “the best.”   
 The notion of the “best” often carried with it a hope of cure and hope for survival, and 
these words were heard repeatedly in discussions as to why people decided to participate 
in research.  The following comments are just a brief overview of how this hope in the 
center’s “ethos” was expressed. One individual remarked, “This is the only place that I 
called because I knew you guys were number one in the world” (Participant 11A). One 
family member said, “We made it [a decision to come to the research center] right away. 
It just really felt like a no-brainer” (Participant 17B). A patient said, “…a few Nobel 
prizes, it’s like why would you go anywhere else” (Participant 3A)? One patient summed 
up the decision to pursue research at the cancer center by saying, “I knew that this cancer 
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center was the best in the world. . . . I felt very confident that this was what I needed to 
do if I expected to have any longevity in my life” (Participant 24A). Another patient 
remarked, “Once we knew what the options were and once we knew more about (the 
cancer center) and literally the worldwide reputation that is has and the depth of 
knowledge and the doctors that are here, that makes it pretty easy” (Participant 23A).  
 
Emotions or Pathos 
  Pathos is associated with an appeal to the emotions. The root of the word pathos 
means to “suffer,” and rhetorically that sense of suffering is conveyed via the evocation 
of the imagination. The power of pathos exists in the artful use of language calculated to 
elicit a response in the listener. Words utilized situate the speaker and the hearer within a 
shared emotional resonance. Within this context, hope is coconstructed between 
researchers and patients/family members as they speak and listen to one another, and 
hope stands as a counter-balance to the pathos/suffering of cancer. In many of the 
interviews, patients said that the participation in research represented a hope for them to 
be freed from the angst and suffering of a terminal illness.  
 The resonance between researchers and patients can be heard in those statements 
where the power of suffering is illustrated. One mother described her young son 
encouraging her to participate in research. “It was so hard,” she said. “I was so sick with 
high-dose chemo and he was right there, like my little cheerleader [telling me] ‘you can’t 
give up now, you’ve come this far,’ [which makes me feel] I can’t quit” (Participant 
10A). A young woman relayed this as her experience: “I’m glad I made the right decision 
[to come to the cancer research center] . . . the body pain, the throwing up, seeing blood . 
. . the diarrhea, the uncontrolled urine . . . the hearing loss, the uncomfortableness, and 
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now the numbness in my leg and arms, but nothing compared to the hospital, so I’m 
grateful, because I think now I am cured” (Participant 18A).  
 
Dynamics of the Rhetorical Process 
    The individual coding of statements into the categories of logos, ethos, and pathos 
provides some insight into the decision-making process, yet it falls short of 
demonstrating the full dynamics of persuasion. In the discussions about what influenced 
participants’ decisions to participate in clinical research, most cited all three categories of 
logos, ethos, and pathos. See Table 10 for a summary of these statements.  
Participants generally had an intellectual or cognitive awareness of what the 
research participation entailed, which represents the logos or information about their 
disease. At the same time, the component of the researchers’ reputations and the 
endorsement of the center’s expertise by referring physicians confirmed the ethos or 
credibility for the participants.  Finally, participants acknowledged the pathos, or 
emotional influence of facing possible death and decreased time with loved ones as a 
component in agreeing to enroll in clinical research.  
It is clear that no single element determined the decision to participate in clinical 
research, but rather that the decision was the combination of considerations that resulted 
in an affirmation of research as the ultimate choice. Most participants held a strong 
conviction that the research offered by the specific researcher at this specific center 
would afford them the best hope of survival.   
 




 Within discourse, there are multiple reflexive components, including speakers, 
hearers, and subjects. In recruiting for clinical trial participants, the previously discussed 
elements of rhetoric or persuasion provided a framework upon which to understand 
enrollment for cancer research participation and the power of the hope imperative. Given 
the theoretical foundation that language is not merely words but generative of ideas and 
meaning, the habitus of speakers and hearers is one way that the dynamics of persuasion 
can be understood. 
  Scientists and physicians engaged in investigation of new interventions to 
improve cancer outcomes are recognized and honored by society for their contributions. 
Social conventions like Nobel Prizes, the MacArthur Award, publication in scientific 
journals, and presentations at conferences generally provide the foundation upon which 
ethos, or credibility, is built. The option for a possible cure for cancer and relief from 
suffering evokes a strong emotional response in patients, family members, and the 
researchers engaged in clinical investigation, constituting the second category of rhetoric, 
or pathos.  
Logos is the distillation of a “rational” body of evidence that appears to confirm 
the “truth” or hope science holds for the new cancer clinical trial.  Offering of the trial to 
eligible patients and the patients’ subsequent enrollment into the trial can be viewed as 
the reasoned and rational foundation of scientific process. It is not only the individual 
level of practitioner/institutional accomplishment (ethos), the amelioration of the 
individual’s suffering (pathos), or the scientific advancement of an intervention (logos) 
where the habitus of hope is found. 
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  Habitus organizes practices and perceptions so that shared meanings are 
reflexively uttered and understood. Without habitus, the other three components—ethos, 
pathos, and logos—render persuasion only a vague invitation. When coupled with the 
social power of shared assumptions that confirm the value of research, its potential for 
cure, and the  resulting possible amelioration of suffering, then there is an imperative to 
invest in hope.  
 This strong personal investment or hope for success in clinical research is 
manifest in many ways.  For instance, publication bias is a phenomenon that latently 
determines which studies are published; generally, only those studies reporting positive 
findings are published (Walters, in press; Ioannidis, 2005).  Publication bias prevents 
learning from trials in which patients do not show significant improvement or trials that 
do not support the initial hypothesis. Publication bias also may explain the titling of 
abstracts and study findings at international meetings. Estey and others (2006) have 
undertaken a review of all American Society of Hematology (ASH) abstracts presented 
from 1993 to 2001. Their findings show that “81% of all drugs reported as positive for 
acute myelogenous leukemia therapeutics remain, at least 5 years from date of ASH 
publication, either outside the scope of clinical practice or unevaluated in randomized 
trials” (Estey, Bedikian, Witter, Pierce, & Giles, 2006). This low rate of advancement of 
much-heralded agents into further trials or clinical practice is most likely due to the 
agent’s lack of efficacy or unsatisfactory level of toxicity. Estey and others call for this 
publication bias phenomenon to be explored, yet it still remains a common practice to see 
“promising results” published and touted while few new agents are making solid progress 
toward integration into clinical practice or advanced-phase clinical trials. 
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  Most people who are treated on Phase I trials are only eligible for these trials 
because conventionally available treatments have become ineffective against their 
cancers. Research represents an opportunity to evaluate toxicity and possible efficacy of 
new agents. The primary goal of a Phase I trial is to determine safety in dosing of the 
agent. The research question is, “How safe is this medication?” Efficacy is evaluated at a 
later stage of research, yet the assumptions that are communicated in the discourse of 
informed consent for a Phase I trial convey an implicit hope-for-cure. 
 There are many subtle and not-so-subtle ways in which hope is cocreated for 
people with cancer in the realm of clinical care. The language of hope is often used by 
researchers and care providers to couch the various treatment and research options open 
to people with cancer. In scientific literature, the language of hope has a significant 
presence. Literature searches using “cancer and hope” in the title found an increase in 
articles using the word hope in the title. An example from the Journal of the American 
Medical Association brought up an article titled, “New screening methods offer hope for 
more accurate breast cancer detection” (Mita, 2008). Such a title demonstrates how 
science and cancer care are explicitly linked to articulations of hope, thus invoking a 
powerful societal response to the evidence-based work. Given that providers and patients 
rely on the construct of hope in the clinical management of the illness and in the options 
for treatment and research participation, further studies are needed to determine how the 
language of hope is used and perhaps at times misused. 
 
Conclusions 
 This study set out to examine the habitus of hope and to explore the implications 
of hope in decision-making for cancer research participation.  The discourses of cancer 
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and hope have been so integrally linked in both the professional and personal domain that 
all players—patients, family members, and physicians—bring an expectation of hope to 
the decision-making processes. Hope-for-cure or hope for additional time are ideas 
expressed by cancer patients and their loved ones. The same outcomes of hope-for-cure 
or additional time are desired by researchers and those whose livelihood depends on 
continued research programs for improvement in morbidity and mortality associated with 
cancer care.  
Hope may also represent a coercive influence in the decision-making process for 
people with cancer because it may lead them to decide on options of research that are 
represented as the “only hope” for possible survival. When research participation is 
offered to patients, the discussion and nuanced language used in informed consent 
conferences may lead the patient and family to understand that a particular clinical trial is 
the “best” for them.  It is important to note that the researcher’s utilization of hope is one 
articulated at a societal level, but the perception of research is often expressed as a hope-
for-cure for cancer at the individual patient level (Jansen, 2011; Sulmassy, 2010).  
    The research presented here suggests that researchers and all care providers 
within the context of cancer care should be aware of the power of the hope imperative. 
Communication between patients and researchers may lead patients to perceive research 
as an intervention with certain outcomes as opposed to a process for answering safety and 
efficacy questions regarding a specific research question, a confusion known as the 
therapeutic misconception (Appelbaum, 2004).  
 The main conclusion of this study is that a habitus of hope posits a subtle yet 
powerful imperative for patients and family members within their personal life 
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experiences and expectations as they are making decisions about possibly participating in 
cancer research. An overt hope imperative is posed for patients in the discourse of 
informed consent with general hope in scientific practice and specific hope for a 
successful or promising research trial. Researchers and nurses should strive for awareness 
of the power they wield in supporting patient and family decision-making. The ethical 
challenge is to respect the important work hope may do for people while maintaining 
distinct insight into how coercive a researcher’s or practitioner’s own habitus of hope 
may be for patients. Assumptions should also be examined about what is critically 
constitutive of decision-making. Do cancer patients feel as if there is a decision to be 
made to participate in research?  Or does participation in clinical research exist primarily 
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Age 22–72 35–62 Not asked 

















NA  6 years N=2 
11 years N=3 
18 years N=1 
20 years N=2 
27 years N=1 
36 years N=1 
	  
  





Table 10  









1A “My disease was 
unresponsive to all 
other therapies.” 
“This place had the best 
reputation and my own 
doctor recommended it.” 
“If I didn’t do this I 
would die in two or 
three years.” 
5B “We never once 
thought no, we are 
not going to do 
anything. That was 
not an option.” 
“There was never any doubt 
we were going to the right 
place.” 
“It was life or death.” 
7A “We never really 
were presented any 
other options after I 
relapsed.” 
“My doctor said it was the 
only place to go for what I 
had.”  
“I never really grasped 
that it was really bad 
that my cancer kept 
coming back really fast 
after chemo.” 
9B “Yes it’s her only 
chance; 30% is better 
than zero.” 
“This place is the best in 
the world.” 
“I tell her, I can replace 
anything I lose, but I 
cannot replace you.” 
14A “My doctor was very 
clear that this kind of 
disease is very 
aggressive and the 
only way to get rid of 
it is with a 
transplant.” 
“This is the only option left 
for me.” 
“I need to live another 
five or six years to take 
care of the children.” 
17B “He said . . . ‘will I 
kick myself two years 
down the line 
because I didn’t do it 
when the opportunity 
was there?’” 
“We have always heard it 
was the best place to come 
for a transplant.” 
“He really just wants to 
live longer.” 
18B “I want to know the 
best and I want to 
know the worst. . . . 
the more I get into it, 
the smarter I I’ve 




“[We came] because it’s a 
renowned facility . . . and 
certainly the number of 
transplants that are done 
every year far outweigh 
most facilities around the 
world.” 
“The primary 






THE METAPHORICS OF HOPE-FOR-CURE 
 
Abstract  
The use of metaphorical language is commonplace and can provide concrete 
understanding of complex abstractions for patients with cancer, their family members, 
and their physicians. In discussions about treatment options, research recruitment, and 
prognosis of disease, evaluation is needed as to explore implications of metaphor 
employment.  
The author did a secondary analysis of 109 transcripts of interviews of 55 people: 
25 cancer patients enrolled in Phase 2 clinical trials for hematopoietic stem cell 
transplants (HCT), 20 family members, and 10 physicians. Textual analysis, specifically 
thematic analysis, was used to identify metaphors in the transcripts. Five dominant 
metaphors were identified as most commonly used across groups.  
Metaphors were categorized into five major types across groups: time, journey, 
hands, war, and faith. All the metaphors were linked to the hope-for-cure of the 
underlying hematologic malignancy. Journey was the most commonly used metaphor 
(48–60%) and included the expectation that the destination of the journey was 
amelioration of the disease and survival. Hands and the concept of holding was next in 
usage across groups, ranging from 28 to 40%, and implied a sense of trust in whose hands 
the patients’ life was held. Faith was the next most utilized metaphor (20–40%) and 
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referred to expectations of miracles and a cure. Time, at 20 to 30%, represented the 
concept of being given a longer time to live. War was the last major category, at 20 to 
30%, and referred to treating the disease.  
The high correlation between groups in usage of metaphors may indicate a shared 
understanding of meaning. Differences may indicate a significant disconnect between 
providers and patients/family member and may suggest ethical implications for the 
process of decision-making relative to cancer clinical research participation.  
 
Introduction 
	  	   Patients are referred to quaternary cancer centers by their community oncologists 
to receive care for aggressive and life-threatening illnesses. These patients are offered 
clinical trials for disease amelioration at these referral centers, where clinical research 
decision-making is a large part of their experience. Early-phase clinical trials are not 
intended to be treatment interventions; instead, they are meant to answer safety and 
dosing questions in order to advance clinical science 
(http://clinicaltrials.gov/ct2/info/glossary#phaseII). Research has established that patients 
often perceive early-phase trials as offering therapeutic benefit, and it is this perception of 
promise for cure that prompts their enrollment in those research trials (Kimmelman & 
Palmour, 2005; Moore, 2001; Schutta & Burnett, 2000; Yoder, O’Rourke, & Etyre, 
1997).  Decision-making done in the context of informed consent mandates that people 
are informed both in writing and in face-to-face conferences that early-phase research is 
not for therapeutic benefit—yet the perception of potential benefit persists. Some 
researchers have found that patients do not view research options as a decision to be 
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made, but rather as the next logical step if they wish to continue living (Ferrell et al., 
2003). 
   Optimism has been reported as one reason patients agree to participate in research 
(Horng & Grady, 2003; Jansen, 2006; Jansen, Appelbaum, & Klein, 2011; Sulmasy, 
Astrow, & He, 2010). Optimism, however, does not seem to represent the factual 
cognitive knowledge of the patients studied, but instead seems to stand in metaphorically 
as a hope-for-cure. Metaphors as important parts of everyday language and as 
components in discourse between cancer patients/family members and physicians have 
been examined closely. Some authors have encouraged the use of metaphorical language 
as a vehicle for increasing rapport with patients and families (Reisfield & Wilson, 2004).   
 Metaphors are not just words; they are ideas that map complex abstractions to 
other more familiar structures so that meaning is conveyed. By utilizing a cognitive 
linguistic model, metaphor is defined as coming to know or understand one conceptual 
domain in terms of another conceptual domain. The coming to know—or “understand”—
is accomplished by drawing a relationship between two concepts (A, the source domain, 
and B, the target domain) and is further expanded by establishing “the set of systematic 
correspondences between the source and the target” (Lakoff & Johnson, 1980, p. 6).  It is 
through the correspondences or mappings that meaning is made comprehensible in the 
use of metaphorical language. Conceptual metaphors are rooted in everyday experiences, 
and metaphorical thought is unconscious and inescapable. Metaphors are very often used 
to convey hope, an important concept for people with cancer.  Hope has been defined as a 
“multidimensional” and dynamic process (Lakoff & Johnson, 1980). Hope has been 
described as a strategy for “coping” with cancer (Dufault & Martochicchio, 1985; 
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Menninger, 1959; Thorne, Hislop, & Kuo, 2006) and as a phenomenon worth “fostering” 
in cancer patients (Ebright & Lyons, 2002; Herth, 2000). 
 Since hope is expressed metaphorically, it is important to examine the 
implications of metaphorical language in cancer conversations and clinical research 
decision–making, where the employment of hope is commonplace. What metaphors are 
commonly used by patients/family members and physicians in relationship to cancer 
clinical trial enrollment? Are there differences in the metaphors employed by 
patients/family members and physicians? How do metaphors get used in decision-
making? The purpose of this study is to explore the use of metaphors and to understand 
how metaphorical language constructs meaning for people with cancer, their family 
members, and cancer clinical researchers. 
 
Material and Methods 
Sample and Methods 
The Seattle Cancer Care Alliance (SCCA) is a large cancer referral center where about 
400 hematopoietic stem cell transplants (HCT) are performed each year (FHCRC, 2010).  
Participants for the study were a convenience sample of research patients enrolled in 
Phase 2 clinical HCT trials for hematologic malignancies. Family-member caregivers 
were designated by the patients, and physicians were identified from the allogeneic 
transplant service for participation. Those who agreed to be interviewed included 25 
patients, 20 caregivers, and 10 physicians.  A total of 109 semistructured interviews were 
conducted. Interviews were done before the HCT, at about 80 days after the HCT, and at 
the 1-year follow-up visit to the hematopoietic stem cell transplant (HCT) center. Three 
patients died before day 80, and 5 additional patients died before the 1-year follow-up 
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interview. This sample size was purposefully large enough for qualitative analysis and to 
provide sufficient data for exploration of concepts pertinent to research participation for 
cancer patients and their family members (Sandelowski, 1995).  
The original study and the secondary study were approved by the Fred 
Hutchinson Cancer Research Center Consortium Institutional Review Board (IRB). All 
participants signed consents for the original study, and the IRB granted a waiver of 
consent for the secondary analysis of the data. The transcripts were entered into 
HyperRESEARCH™, a computer software for qualitative data analysis created by 
Researchware of Randolph, MA.  
    Close textual analysis was done and participant utterances in the transcripts were 
coded for metaphor use. Metaphors were technically understood to be correspondences or 
mappings between the source domain and the target domain, with understanding moving 
from the concrete to the more abstract (Kovecses, 2002).  Therefore, anywhere in the text 
where participants used concrete words like next step or climbing a mountain to describe 
the cancer treatment process and the related decision-making process for research clinical 
trial enrollment, the text was highlighted. After all 109 transcripts were coded, the 
highlighted texts were then grouped into one of five major metaphor categories. The five 
dominant categories of metaphors identified as most commonly used by participants were 
time, journey, hands, war, and faith.  
 
Results 
    The patients all had hematologic malignancies, and in order to participate in the 
study, all had to have had a good ECOG performance status (< 2).  As shown in Table 11, 
all participants ranged in age from 22 to 72 and were comprised of 25 men and 30 
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women. Participants were predominantly White and most had some college education. 
Interestingly, 26%—14 of the 55 participants—reported having only some high school or 
a high school diploma/graduate equivalency degree.  
 Five major categories of metaphors were identified in the textual analysis of the 
participants’ interviews: journey, hands, faith, time, and war. Journey was the most 
commonly employed metaphor across groups, used by 48% of patients, 60% of family 
caregivers, and 50% of physicians/researchers. The full display of metaphors by category 
and usage by participant groups can be seen in Figure 1.  
  Across the three participant groups, patients and family caregivers used proportionally 
more metaphors more frequently than did the physicians/researchers. The rate of 
metaphors was 2.0 per person in the patient group, 2.6 in the caregiver group, and 1.6 in 
the physician/researcher group. Due to the small sample size, it is difficult to draw 
inferences about the differences between groups; however, there is a different rate of 
metaphor usage between females (1.48) and males (2.16). Regarding gender, 13 of the 20 
caregivers were female, 11 of 25 patients were females, and 1 of 10 
physicians/researchers were female.   
 Further exploration was done to assess associations among metaphor categories 
across participant groups. The only statistically significant association was between the 
use of journey and time (P=.017, Fisher’s Exact Test, two-sided).  All patients (6/6) and 
physicians (2/2) who used the metaphor time also used the metaphor journey; use of time 
and journey were unrelated within caregiver participants.  
 




Twenty-nine of 55 participants used metaphors of journey. The starting point of the 
journey was the diagnosis, and the destination was the hoped-for cure of the hematologic 
malignancy that had necessitated the early-phase research HCT. For a synthesis of how 
metaphors of journey were mapped from the source to target, see Table 12. 
 People used words like path and road to describe the trajectory of cancer care and 
research treatments. The methods of travel varied from “steps” to “sailing” to “climbing.” 
Most often, patients and family caregivers referred to their referring physicians and the 
researchers at the center as navigators of the journey. Less frequently, reference was 
made to God as “guiding the course.” Generally, the destination was hope-for-cure and 
continued life.  Participants used phrases like steering and driving to indicate how 
decision-making was done relative to care and research participation. Synthesized 
representational quotes from participants follow: 
• Participant 1A: “I want to get to a place where you can say this is all over and I can 
get on with my life.” 
• Participant 2B: “I believe God is a research scientist and he is guiding us down this 
path.”  
• Participant 3A: “It’s just what’s happening, what’s coming down the road because it 
has been my philosophy since 1996 . . . the next thing that comes out is going to be a 
little bit better.” 
• Participant 3B: “For the first time in 9 years I feel like there is a light at the end of the 
tunnel.” 
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• Participant 5A (describing the course envisioned after undergoing the HCT): “I am 
going to drive ahead day by day.” 
• Participant 8A: “I believe in God . . . and I know that this is the direction he has led 
me to.” 
• Participant 10A (speaking about how her young son had helped influence the decision 
to go for the HCT and to travel to the cancer center): “My husband said, ‘he is the 
best navigator.’” 
• Participant MD 10 (describing a story of a patient he had referred to an early-phase 
research HCT); “He said, ‘I’ve reached the end of the road, I mean my leukemia . . . 
so I am going to take my chances here.’”  
 In their simplest expressions, the metaphors of journey used by the participants 
signified a sense of life as a trajectory. When participants discussed decisions about 
research participation, the metaphor of journey was most commonly understood as 
traversing a course clearly marked by the milestone of cancer diagnosis. Additional 
milestones were events such as remissions, relapses, and cycles of chemotherapy.  The 
date of diagnosis marked a dramatic change in the previous directions of the individuals’ 
journey.  
When people spoke of who was “steering,” who was “in the driver’s seat,” or who 
the “navigator” was, these metaphors contextually addressed the issues of control, choice, 
and range of available directional options. While the journey metaphor was not 
unexpected in the discussions of participants, it took on complex new dimensions when 
placed in the context of a life-threatening illness.  While a journey can a be seen as a 
single “trip” or an excursion, most cancer patients and family members clearly saw the 
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current “journey” as one starting from initial diagnosis and continuing to an eventual 
destination that was hope-for-cure.  
 Any journey has a temporal component that spans time and space. In these texts, 
people spoke of the journey as being “on the road,” “on a path,” “driving,” or “taking 
steps” toward a destination. Some spoke of “climbing” and taking “new roads or paths”; 
in those cases, the metaphor of journey communicated the unfamiliarity of the terrain, the 
obstacles encountered, the difficulty of summiting the terrain, and the very real option 
that this journey could  mean “the end of the road”—death—for the individual patient.  
 
Hands 
 Eighteen participants used the metaphor of hands in the discussions regarding 
their decision to participate in cancer research. A conventional understanding of the 
source domain of hands targets issues of control and trust. Patients and family caregivers 
spoke of “hands” they were in as they progressed through the HCT. Also, the image of 
the science and the cure going “hand in hand” connoted serendipity between the research 
and possible curative treatments. The metaphor of “hands” also offered a humanizing of 
the research process, bringing in a more accessible focus when compared to the complex 
language of human leukocyte antigens (HLA) and major histocompatibility complex 
(MHC) used to explain the early-phase research HCT. See Table 12 for metaphor 
mappings of the source and target domains. Selected representational quotes follow: 
• Participant 11A (describing who he sees as being in control of his life and his choices 
regarding cancer research participation): “I have come to a point where it’s out of my 
hands.”  
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• Participant 13B (family caregiver discussing how the referring physician offered her 
and her husband reassurance about the decision to travel to the cancer referral center 
for an early-phase research HCT): “He said, I feel like you will be fine, you’ll be in 
good hands there.” 
• Participant 17B (a family caregiver characterizing how he views embarking on the 
research HCT): “I definitely feel the fear . . . and I give it over into God’s hands and 
say,  ‘OK, we are at the best hospitals, we have the best doctors, and we have the best 
nurses. And we have you there God, to help us and we are going to get through.’”    
• Participant 23A (a patient articulating the vision of research and clinical treatment as 
almost synonymous actions): “I am a part of research, but in doing that . . . it’s a part 
of the treatment, being a part of the research. They kind of went hand in hand. I did 
not segregate it that much.”    
• Participant 24B (using the image of hands as holding/carrying the patient through the 
research HCT): “They don’t have as much hands on as you do down here.”  
• Interviewer: “Is that a good thing?” 
• Participant 24B: “Yes, it’s real nice if you are doing it for the first time. . . . You kind 
of get carried through the process.” 
• Participant MD3 (physician demonstrating how he addresses patients who consent for 
research HCT): “We will try our best to help you live, but we are limited in what we 
can offer, and what will happen will happen. You will either live or not. And it will 
be in God’s hands.” 
 The metaphor of hands was used as participants spoke about the issues of control. 
Many said that their arrival at the quaternary cancer center and enrollment in clinical 
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research meant that the future was “out of my hands.” Hands were a way of embodying 
how patients and family members transferred control of their lives and care of the patient 
to the research center. When researchers acknowledged that patients and family members 
“put their lives in our hands,” they recognized the power held by the clinical research 
team and the trust placed in them. Another metaphorical use of hands was seen in how 
people discussed balancing the demands of being in cancer research treatment—treatment 
became just one more thing for patients to juggle.  Support and assistance were also 
intertwined with the metaphor of hands when participants spoke of “being hand-in-hand” 
with the doctors and nurses in the center or when they stated how staff “held our hands” 
through the whole process of the transplant.  A direct relationship to hope-for-cure was 
evidenced in the participants’ use of metaphors like “cure is just within our grasp now,” 




 Eighteen of the 55 participants used metaphors that could be categorized as faith. 
Most often the source metaphor of faith had as its target trust in the early-phase research 
HCT (see Table 12).  Expressions of faith included references to faith in God, but also 
included faith in science and in the reputation of the cancer referral center.  
The concept of fate guiding the process was heard from multiple participants. 
Representational quotes follow: 
• Participant 2A: “We prayed for the best cure.” 
• Participant 4A: “I . . . believe in . . . fate leading the way a little bit: . . . a thing is 
right when all the gates open. They just keep opening.”  
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• Participant 7B: “I wanted to give him the best chance to live. . . . This is the only 
chance that I think he’s going to have. . . . It’s a miracle.” 
• Participant 12B (a family member relating how faith in the center drove the decision 
to participate in cancer research): “We just had incredible faith in [researchers at the 
referral cancer center].”    
• Participant 21B (a family caregiver describing how faith in God and prayers 
complement the early-phase HCT): “It’s in God’s hands and He’s the only one can 
decide how it’s going to come out. We’ve got family all over the United States and 
we’ve got prayers going.”  
    The metaphor category of faith was primarily used to signify the participants’ 
trust in or reliance on someone beyond themselves.  Some spoke of expecting “miracle 
cures” from God, science, or a combination of both. One participant believed that “God 
was a research scientist” who was going to cure his son. Some were less specific in 
whom their trust was directed, stating that they were waiting on “the big plan out there.” 
One participant spoke about the opportunity to come to the center as a moment when the 
“stars aligned” and all the “best researchers came down from Mecca” to see his loved one 
who was there for treatment of acute myelogenous leukemia. Others spoke of being “led 
by God” or “led by fate” to be treated at the research center. Several families spoke of 
coming for a transplant at the center because the center is “the best place to go,” 
signifying a substantial trust in science and trust in the reputation of the researchers. 
Participants also offered accounts of trusting in “the prayers of all the people back home” 




 Approximately 27% of participants (15/55) used the metaphor of time to explain 
how they decided to participate in an early-phase research HCT. The metaphor of time as 
source domain often had as the target domain the longevity of the patient’s life. Time also 
framed the incremental hope that life would be saved or extended by the decision to 
participate in research. Expressions of time held a poignancy of urgency in the face of 
questionable odds. Time was also seen as the ultimate judge of success (see Table 12). 
 The metaphors of time are synthesized as follows with representational quotes: 
 Participant 7B (a family caregiver acknowledging that timing of the research HCT 
had created the best chance at a successful outcome): “I think we have really been 
fortunate, really blessed on all our timing and doctors working with [the patient].” 
 Participant 9A: “But my understanding right now is that there is really nothing else to 
try for a cure. . . . it might have worked this time. Time will tell.” 
 Participant 11A: “I understood it was all research . . . I just did it one day at a time. . . . 
I knew there was a chance it [HCT] was going to work and there was a chance it was 
not going to work.” 
 Participant 12A: “At least this [HCT] is a chance, although it’s a small chance, but it 
is a chance . . . that I can be cured. And if not cured, maybe extend my life some.” 
 Participant 17A: “[The HCT might] hold it back . . . or at least . . . buy time and 
possibly . . . have long-term success.” 
 Participant 19B: “We did not question [HCT]. . . . we wanted to get on it too, his time 
was ticking already.”  
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 Participant 21B: “We’ve calmed down . . . the crying, the screaming, and the yelling, 
all this is over with and we are just going to take it one day at time. Just stay relaxed, 
enjoy day by day.”  
Time as metaphor was significant because in addition to being directional, it had a 
discrete point of beginning—the diagnosis of the hematologic malignancy. Included in this 
category of time was the recognition of looming finality—possible death. Time was at once 
a metric for measuring survival and ultimate cure, as well as a threat because  
“time is ticking away.” Participants talked of being “robbed of time,” of needing “more 
time to see the kids grow up,” and the “timeliness arrival” at the center. Time was also seen 
as the ultimate evaluation of successful attainment of cure—“time will tell,”  “we are 
taking it a day at a time and we know that his time is not up yet,” and “the timing is 
right for us to get ahead of the disease.”  Overall, time as an external measurement could 
be seen as a desired end point to extend the life of the patient enrolled in the research 
clinical trial, and also as a possible uncertainty of a time in the future with unknown 
outcomes. Time was both a comfort and a potential threat, as it was balanced against the 
aggressiveness of the patients’ cancer and the available days to live. 
 
War 
Twelve participants invoked metaphors of war or battle in the transcribed 
interviews. Proportionately, the physician group used words that were metaphors of war 
more than either the patients or the family caregivers.   
War and cancer have long been linked historically. The most common source 
domain for war is cancer, and the target is victory over the disease. Many concepts are 
illustrative of correspondences or mappings with the metaphor of war. These include 
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bullets—chemotherapy, radiation, or even the HCT—all of which are meant to “kill” the 
cancer cells. Other corresponding concepts can be seen in the use of words like fight, 
beat, shoot, and pull the trigger (see Table 12). Representational quotes follow: 
• Participant 2A (a patient describing how he intended to have the HCT and his 
family’s prayers “fight” the leukemia): “Leukemia is something that can be fought on 
every hand.” 
• Participant 12B (a family caregiver describing how she could agree to the HCT 
because of her husband’s will to “fight” against the disease): “I draw my strength 
from him because he fights.” 
• Participant MD3:  “They want to be alive for a long time. . . . They want to fight it 
and stave it off and they want to eliminate the disease . . . to be around for other 
family members. . . . They have other things they still want to do.” 
 Surprisingly, given the predominance of the official war on cancer, metaphors of 
war were one of the least used by participants.  Implications of “fighting” and “not giving 
up the fight” seem most often to address the motivation to defeat cancer and hope to 
attain a cure.  War did not appreciably add to the understanding of decision-making 
relative to cancer research participation.  
 
No Use of Metaphor 
 Seven participants—two patients, three family caregivers and two physician 
researchers—did not use any metaphors from the five major metaphor categories 
identified (journey, hands, faith, time, or war).  These same participants also did not use 
any metaphors as evaluated in the interview transcripts.  
 




Resonance between individuals due to life experiences and cultural discourses 
help reinforce common, conventional metaphors (Kovecses, 2002).  The word cancer is a 
metaphorical expression believed to be first used in medical literature, employing the 
Greek word karkinos (crab), around 400 BC. Another metaphorical expression comes 
from the Greek word onkos (now the root of the word oncology), referring to the burden 
carried by the body of one afflicted with cancer (Muherjee, 2010).  
 In 1971, President Richard M. Nixon declared “war” on cancer and designated the 
Army’s Fort Detrick, Maryland (a decommissioned biological warfare facility), as a 
cancer research center (NIH).  Dominant metaphorical themes of “war” and “battle” 
relative to cancer research and treatment have been identified by researchers (Learner, 
2001; Lupton, 2003; Mitchell, Ferguson-Pare, & Richards, 2003). The expectation that 
patients accept these militaristic metaphors has met with sharp criticism and even a call 
for a metaphor-neutral zone to be applied to cancer conversations (Sontag, 1990).  
The use of metaphor in cancer conversations is neither good nor bad and always 
needs to be viewed contextually (Reisfeld & Wilson, 2004).  The participants in this 
study used metaphors to structure the experience of deciding to participate in cancer 
research. In this structuring of experience, there is a strong element of hope-for-cure.  
The desire by patients and family members for research to be curative is well documented 
(Bierdrzycki, 2010; Jansen et al., 2011; Shannon Dorcy & Drevdahl, 2011).  
 Metaphor as a linguistic and intellectual device does not abandon one 
signification for another. Its power and usefulness is that it stands related to two 
significations at once. None of the metaphors used by participants as recorded in the 
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transcripts achieved the level of high poetic art. Indeed, many were hackneyed and little 
more than clichés. Spent, worn, and tired as some of the participants may have been, they 
were nonetheless capable of communicating something of psychological and intellectual 
meaning and importance.   
    Both journey and time as metaphors are deeply entrenched ways of thinking about 
and understanding life. The discourse of cancer research is replete with the use of 
metaphors (William-Camus, 2010), and so it is no surprise that most study participants 
used metaphors in the transcribed interviews. Perhaps time is linked to journey because 
journey has the implicit underlying structure of time and flow.  
One of the inherent dangers of metaphors is that misleading assumptions may be 
made about what the speaker intended by invoking a specific metaphor.  Communication 
between researchers, patients, and family caregivers plays a significant role in how 
patients predict the outcomes of clinical research participation (Thorne et al., 2007). How 
researchers tell the story of the research clinical trial and relate possible outcomes of 
clinical trial participation helps create the basis for the metaphorical hope-for-cure. 
Metaphors that target hope-for-cure are not attributable only to patients and family 
members, but to researchers as well. 
 
Ethical Implications 
    This study adds to a body of literature that suggests that hope—specifically hope-
for-cure—is the motivation for people participating in early-phase clinical trials. This 
hope-for-cure raises the ethical concern of coercion in the decision-making process. 
Could the use of metaphors actually structure the decision-making so as to relegate 
participation in clinical research to merely taking the “next step” in a long “journey”?  
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When the inaccurate estimation of risk is pervasive, are there standards by which the 
erroneous perceptions of risk can be corrected? The cultural expectation for “looking on 
the bright side” was critiqued and condemned as detrimental to patients and self-serving 
to cancer researchers and nurses, since hopeful patients are easier and more compliant 
(Ehrenreich, 2009). 
  The formulaic following of all the federal mandates for informed consent clearly 
still leaves room for consideration of how best to assure that vulnerable people are able to 
make decisions regarding research participation without the metaphorical presence of 
coercion. Time needs to be spent helping patients and family members clarify what they 
desire from their participation in the research study. Researchers and all cancer care 
providers need to be aware of the conventional metaphors used by they themselves as 
well as by patients and family members.  
 
Limitations 
 This study is a secondary analysis, so no questions were posed to the participants 
to directly ascertain use of metaphors. The sample of 55 individuals does not allow for 
generalization to other larger groups of cancer patients, caregivers, and physicians. The 
sample also has little racial and ethnic diversity, limiting how much can be gleaned about 
how other more diverse cultures and populations might have used metaphors. Metaphors 
were generalized, but did have cultural variations.  
The use of semistructured interview tools also may have limited the responses of 
participants and so resulted in fewer uses of metaphors. This was a qualitative study, so 
interpretation is relative to the researcher’s specific analysis. Literature supports that both 
qualitative and quantitative data need to be used to establish evidence-based standards for 
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 This study provides evidence of how patients, family caregivers, and 
physicians/researchers structure metaphors in the process of decision-making for cancer 
research. The findings indicate that hope-for-cure is the target domain of all five of the 
dominant structural conceptual metaphors that were used. Hope-for-cure is a powerful 
and sometimes overriding dynamic for participants in clinical trials. The answer is not to 
establish a metaphor-free or hope-free zone.  Further research needs to be done to 
establish ways in which hope-for-cure can be realistically balanced with early-phase 
clinical trial participation.   
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Table 11  
Participant Characteristics (N=55) 
Characteristic Participants 
Age range  22–72 
Female No. (%)   30 (55%) 
Race/Ethnicity  No. (%)  
African-American 2 (4%) 
White 48 (87%) 
Asian 2 (4%) 
Hispanic 1 (2%) 
Native American 2 (4%) 
Patients’ Diagnosis No. (%) (N=25)  
Acute myleogenous leukemia 6 (24%) 
Acute promyleocytic leukemia 1 (4%) 
Chronic lymphocytic leukemia 1 (4%) 
Hodgkins disease 1 (4%) 
Multiple myeloma 5 (20%) 




Highest level of education completed 
No. (%) 
 
Some high school 2 (4%) 
High school/GED 12 (22%) 
Some college 9 (16%) 
College graduate 12 (22%) 
Some graduate school 1 (2%) 
Graduate degree (including MDs) 18 (33%) 
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Table 12  
Conceptual Metaphor Mappings 
JOURNEY 
Source Target 
JOURNEY CANCER DECISION- MAKING 
Travelers Patients, family & physicians 
The journey Course of cancer 
Distance traveled  Events like remissions, relapses since 
diagnosis 
Obstacles encountered Toxicities & adverse events related to 
therapies 
Decisions about which way 
to go 
Choices for cancer interventions 
The destination Cure 
The navigator Researchers and other health care 
providers, family members 
Driving/steering Who is in charge of the journey 
Steps or walking Incremental progress in the course of 
cancer treatment 
Sailing A course somewhat “uncomplicated” 
and assisted by forces beyond self 
Path, road Cancer treatment as a charted territory 
Climbing Ascent of difficult terrain 










The increments of time Days of survival 
The judgment of “too late” Uncontrollable disease progression 
The judgment of “timeliness” Arresting of disease process 
Waiting on time Potential of cure 
Buying time Extending life  
“Time is up” Death 
Window of opportunity Time right for possible cure 
“A day at a  time” Guarded expectations of future 






Whose hands Patients’, families’, physicians’, or God’s 
What is being held Life of the patient 
“Holding on” Continuing to hope in treatment or 
research process 
“Letting go” Trusting in the research/treatment 
process 
“Held our hand” Support for patient and family 
“Trying to juggle” Coping with demands of cancer 
treatment 
 





FAITH TRUST IN RESEARCH 
Led by God Discernment about cancer research 
participation 
Expecting a miracle Research outcomes=cure 
Trust in fate Research team and interventions will 
bring positive outcomes 
Trusting in the big plan Trust in God, science, or  forces beyond 
individual  
“Ray of sunshine” Option for research therapy 
Light or “light at the end of 
the tunnel” 
Relief from anxiety, pain, uncertainty 
“Out on a limb,” “holding on 
to the outer branches” 





WAR ANTI-CANCER THERAPY 
Battles Rounds of chemotherapy 
Soldiers Patients, families, physicians 
Ammunition  Treatment or research process 
Continue the fight Stay in treatment or research process 
Only shot at life Research participation 
Victory Cancer is destroyed 










    The purpose of this discursive study was to explore hope as articulated by 
patients, family members, and investigators in the decision-making process for 
participation in cancer research at a quaternary cancer center. The conclusions from this 
study answered the research questions, and the findings addressed three areas: (a) the 
discourses of hope that influence how people construct hope; (b) the practice of hope 
relative to decision-making for cancer research participation; and (c) the assumptions 
held by investigators relative to cancer research participation. Following is a discussion 
of the major findings and conclusions drawn from this research, followed by a final 
reflection. 
 
Discourses of Hope 
    The first major finding of this research was that most of the healthcare literature 
on hope originates from a singular philosophical approach, one that reifies hope as a 
positive thing.  Hope is commodified in the daily practice of cancer care. Further, talk of 
hope is often a scripted performance that can be coercive when people with life-
threatening illnesses are expected to “keep trying” and to “not give up hope.”  Patients 
are then labeled “noncompliant” or “dysfunctional” when the clinical choices made do 
not agree with what providers judge to be the best or the most hopeful option for patients.  
 
   
	  
110	  
Practice of Hope in Cancer Research Participation 
   The second major finding in this research was that patients, family caregivers, and 
researchers in the quaternary cancer center all are invested in hope relative to decision-
making for research participation. An overt hope imperative is posed for patients in the 
discourse of informed consent, in scientific practice generally, and specifically in terms 
of discussions regarding successful or promising research trials.  While the reputation of 
the cancer center, trust in the researchers, and the emotional context of a diagnosis of 
cancer structure the social space in which patients agree to research participation, that 
space is concurrently structured by the brokerage of the institution and participating 
physician researchers with those who promote research.   
 
Assumptions of Investigators 
  The third major finding in this research was that the hope-imperative was 
operative in physician researchers as well as in patients and family caregivers. Although 
the physicians generally acknowledged that individual patients diagnosed with advance-
stage hematologic malignancies may not be cured, there was an overriding habitus that 
their research was imbued with the hope-for-cure.  While researchers all verbalized 
commitment to discharging the legal and moral obligations of the federally mandated 
elements of informed consent, some also recognized that patients had already made their 
decisions to participate in clinical research prior to arriving at the center.  
 
Recommendations 
   Based on research findings, the author has recommendations for: (a) educational 
curriculums of nursing and medical schools; (b) the clinical practice of nurses and 
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researchers in cancer centers; (c) policy formation at the national level; and (d) further 
research.	  
 
Recommendations for Educational Curriculum Development 
   These findings have implications for the education of all clinicians, researchers, 
and institutional review board (IRB) members. In order to assure that we are able to 
engage in research with patients, we need first to acknowledge that the vulnerability 
caused by suffering and illness seems to have created a societal imperative to “hope.” 
Reflection on researcher motivation and values needs to be a part of graduate studies. The 
idea that researchers should “bracket” themselves and see the verbatim translation of 
patient interview data as something objective and free of interpretation is unrealistic. All 
research is interpreted by the researcher and the process of analyzing data. 
  The curriculums for research courses as well as for ethics courses need to include 
examinations of the role hope plays in decision-making. The practice of objectifying 
hope and allowing only the phenomenological philosophical framework to serve as the 
foundation for qualitative research limits the scope and inquiry that can be done. Faculty 
need to expand the repertoire of research models to include more than theory-generation 
and concept-analysis.  Additionally, IRB members should be offered classes that broaden 
the awareness of the language of hope and how use of that language may possibly be 
coercive for patients.  
  
Recommendations for Clinical Practice 
  Hope is a powerful cultural discourse. Cancer researchers and nurses must be 
careful not to coerce people into clinical trials by their personal investment in hope.  
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Enrollment in a cancer clinical trial is often couched in expressions that convey a sense of 
power to those offering participation,  insuring  the economic capital (for example, that of 
a drug company that has high stakes in the trial on human subjects) and promoting the 
social capital of the arbiters of admission (the researchers).  In turn, these forces 
downplay the value of the role of potential participants, ignoring the social capital these 
individuals bring to the table in the classification of eligibility for the study. Absent these 
individuals consenting to research participation, there would be no enactment of the 
particular protocol, and participation—whatever its motive force on the part of the 
consenting participant—is essentially constitutive of its actuation.  
 The informed consent conference provides a special kind of milieu or social space 
where, among other elements, a set of power relations is established or at least 
maintained. Traditionally, consent has been used as both a noun and an intransitive verb. 
More recently, consent has become a transitive verb as seen in the following uses: “I need 
to consent the patient,” or “Has the patient been consented yet?” There are implications 
in the metamorphosis of the word consent into a transitive verb.  As a noun, consent 
conveys the meaning of permission, approval, and agreement. As an intransitive verb, 
consent means “to agree to do something,” “to give permission, approval, or assent to 
something proposed.” Consent as an intransitive verb connotes agency and autonomy. To 
consent someone—using consent as a transitive verb—connotes an act of bringing into 
compliance or of establishing  acquiescence.  The patient in that usage is no longer an 
agent or a subject but an object—truly a patient, one acted upon. A complete moratorium 
on using consent as a transitive verb would not only delight the grammarian’s purist 
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heart, but restore dignity and power to the person who enrolls in clinical research through 
the informed consent process. 
 
Recommendations for National Policy 
  The complexity surrounding the language of hope means that ensuring the 
integrity of the process of informed consent requires more than simply imparting 
dispassionate, adequate information. In fact, consciousness-raising about the mandated 
expectation of hope needs to be discussed at forums such as Public Responsibility in 
Medicine and Research (PRIM&R) and at local institutional review boards. Our current 
regulatory processes are careful to avoid any semblance of promising “cure,” yet that is 
what most people cite as the reason for consenting to participate in cancer clinical trials. 
We need to seriously evaluate how hope is firmly entrenched in the rhetoric and 
assumptions of the consent process. Clearly, the federal system has strengths, but the 
process of informed consent should not be seen as something static but rather as 
something in need of further and continuous  refinement. Autonomous, coercion-free 
decision-making for vulnerable people with life-threatening illnesses cannot be a 
perfunctory process. 
 
Recommendations for Further Research 
  Little research has been conducted that examines the influence that the language 
of hope has on decision-making for participants in cancer clinical trials, even though 
multiple studies have reported that patients decide to participate in clinical trials because 
these trials offer “hope” for survival. The next step in this current research program 
would be to do a prospective, multi-site study to examine how several centers who do 
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early-phase cancer research handle informed consent. One of the most promising 
opportunities is to introduce palliative care into the consent process and research 
intervention. Palliation of symptoms and quality of life are elements that could broaden 
the discourse as it exists today and move early-phase research away from hope-for-cure 
to address issues of quality of life and amelioration of suffering. 
 
Final Reflections 
  Pulitzer Prize-winning novelist N. Scott Momaday regularly told the story of the 
Kiowa Arrow Maker, a tale he described as being “superbly metaphorical.” Sitting one 
evening in his teepee with his wife, he straightened his newly made arrows; using his 
teeth as an anvil while bending the arrows with his hands; he tested their trueness in his 
bow. At one point, he nodded to his wife and drew her attention to a small chink in the 
wall of the teepee where the lacing had failed between two of the buffalo hides. His eyes 
spoke and told her that someone was lurking outside their home.  
“Let us go on talking as if of ordinary things,” he whispered to her after a pause, 
all the while continuing to straighten and test his arrows. Finally he raised his voice 
slightly and carefully, deliberately spoke these words: “I know that you are out there. If 
you are my friend, you understand Kiowa and you will reveal yourself to me. But if you 
do not understand what I am saying, you will remain silent and I will know who you are.” 
Having spoken, he continued to test his newly made arrows. Flexing the bow high and 
low about the teepee until he drew it even with the chink, he let the arrow fly and killed 
his enemy (Momaday, 1997, pp. 9–10). 
 The arrow maker is quintessentially the word maker, as Momaday pointed out—
in effect, the poet. In his shift from ordinary speech—“Let us talk as if of ordinary 
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things”—to the words of carefully chosen deliberative speech, the arrow maker revealed 
the power of metaphor. He actually knew what he had not known before. Disadvantage 
became advantage as discourse became an extraordinary moment of discovery. The tables 
were turned. The threat of death became the promise of life. 
  In the spirit of the arrow maker tale,  the ordinary speech of the informed consent 
conference ought to be allowed to become what it inchoately is: a moment of privileged 
communication—privileged not only in the sense of confidential, but under the more 
important aspect of open to opportunity. This opportunity could and should embrace a 
broader discussion of the meaning of hope, and should be seen as a mutual quest for 




























Study ID#_____________  Insurance_____________________(Private, Public, 
Private Pay) 
Date__________________  UMR#_________________  UPN______________ 
DOB__________________  Karnofsky_______________ 
 
Gender:  Male Female 
 
Ethnicity:    
Hispanic    
Non-Hispanic   
 
Race: 
American Indian or Alaska Native   Asian 
Black or African-American    White 
Native Hawaiian or Other Pacific Islander    
Other (please specify)______________________________________________ 




Annual Household Income: 
$0-$10,000    $50,001-70,000  Over 
$150,000/year 
$10,001-$20,000   $70,001-100,000 
$20,001-50,000   $100,001-150,000 
 
Family Makeup: 
Number of dependents:_______ 
Number of individuals in your household:_______ 
 
Education:  What is the highest level of education you have 
completed?________________________________________________ 
Occupation: What type of work did you do in your most recent 
job?__________________________________________________________ 
 
Please check the one phrase that best describes your level of activity during the past 2 
weeks. 
I can do my normal activity, and I have no complaints about my health.  
I can do my normal activity, but I am not completely healthy.  
I can do my normal activity, if I make an extra effort.  
I can take care of all my personal needs, but I cannot do my normal activity or work.  
I can take care of most personal needs, but I sometimes need help.  
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I can take care of some personal needs, but I often need help.  
I need special care and help with my personal needs most of the time.  
I need special care, sometimes in the hospital.  
















Questions/probes for patients: 
1. When did you make the decision to participate in this research? How were you 
asked to take part in this research? 
2. Describe the information you used to help you make the decision. How was the 
information about the research given to you? 
3. What and/or who influenced you most in making your decision? 
4. Who do you see as the primary decision-maker? 
5. Why did you make the decision that you did? What were you thinking about while 
you were making your decision? 
6. Which relationships have been influential in helping you reach a decision? Are 
there any relationships that have hindered you reaching a decision? 
7. Describe the relationship you have with the research team. 
8. Describe factors in your personal life that helped or hindered your decision-making 
(e.g., prior experiences, beliefs, faith). 
9. Describe the circumstances that lead to your coming to FHCRC (probe for relevant 
details about the referral process, e.g., resource availability, time from diagnosis, ability 
to obtain visa, insurance coverage)  
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10. Is there anything else you want to share? 
 
Questions/probes for family caregivers/physicians: (physicians script italicized when 
different)) 
1. When and where (did your)(do)  family member make the decision to participate in 
this research? How were they asked to take part in the research? 
2. Describe the information(you provide to patients and family members) (your family 
member )used to help make the decision. How was the information about the research 
provided? 
3. What and/or who (influences patients and family members) influenced (your family 
member) most in making your decision? 
4. Who should be the primary decision-maker? 
5. Why do you think (patients make the decisions they do) (your family member make 
the decision that he/she did)? What do you think (patients think when making the 
decision) he/she was thinking about when he/she made her/his decision? 
6. What is your role in the decision-making? Did the two of you come to the same 
decision? Describe that process. 
7. Which relationships (have been) influential in helping (patients and families) (you 
and your family member) reach a decision? Are there any relationships that hindered 
reaching a decision? 
8. Describe the relationship you and (your family member) (the patient) have with the 
(research team) or (family). 
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9. Describe factors in (patient families) (your family member’s) personal life that 
helped or hindered decision-making (e.g., prior experiences, beliefs, faith) 
11. Describe the circumstances that lead to (patients and families) (your family 
member) coming to FHCRC (probe for relevant details about the referral process, e.g., 
resource availability, time from diagnosis, ability to obtain visa, insurance coverage). 
10. Is there anything else you want to share? 
 
 
 
 
